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 Summary 1
 
English| To overcome potential shortcomings of classical monolayer cell culture and 
animal models in drug discovery, complex three-dimensional cell-based cancer 
models entered the stage in the last years. These artificial tissue surrogates serve as 
suitable ecological niches for a multitude of cell types. They allow mimicking the 
pathophysiological complexity and cellular heterogeneity of cancer in vivo. Therefore 
they might lay the foundation for a robust and reliable in vitro cancer model. In cell-
based three-dimensional models it is possible to tailor the appropriate 
microenvironment for many individual tumors. However, many research efforts are 
still necessary in order to fully integrate 3D models into the drug discovery strategies 
of pharmaceutical industry.  
 
In this work we established robust and standardized methods to generate 3D cancer 
models on the basis of the human tumor spheroid methodology. Spheroids are 
spherical cell aggregates that tend to form under defined experimental culture 
conditions. Since each cancer cell line required individual conditions to form 
spheroids we used different techniques including Rotary Cell Culture System 
(RCCS), the hanging drop and Methylcellulose-based methods as well as non-
adherent surfaces (Hydrocell™, poly-HEMA coating) to generate spheroids. Due to 
recent advances in the field of biomaterials individually tunable matrices have been 
developed to provide the embedded spheroids with tailored microenvironment. We 
embedded spheroids in natural (Matrigel™, Collagen type 1) and synthetic 
(HyStem™, HydroMatrix™) extracellular matrix (ECM) scaffolds. This facilitated the 
generation of heterotypic co-cultures consisting of tumor and stromal cells.  
We stably transduced lung cancer cells and primary human fibroblasts to express 
fluorescent proteins (EGFP, mCFP, J-Red) which allowed discriminating between 
the different cell types. We used these cells to establish defined co-cultures of lung 
cancer spheroids with human lung fibroblasts that may allow studying tumor-stroma 
interactions. Such co-cultures are considered to be a promising tool in tumor biology 
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for deciphering the effects of tumor-stroma interactions on drug response and drug 
efficacy in the future. We already established an experimental workflow for the 
automatized generation of spheroids and organoids that might be amenable to high-
throughput drug screening (HTS).  
To characterize the cell physiology of organotypic 3D models in more detail we 
performed Affymetrix Gene Chips analyses. We could demonstrate that organotypic 
cultivation in 3D ECM matrices (Matrigel™/collagen) substantially altered the gene 
expression profile of cancer cells. Furthermore using defined phospho-protein 
antibody arrays we revealed differential phosphorylation patterns when cells were 
cultivated in 3D. In particular, we could show that epidermal growth factor receptor 
(EGFR) is significantly hyperphosphorylated in the tested lung cancer cell lines 
cultivated in 3D. In line with these findings the 3D models exhibited a significantly 
increased sensitivity to the targeted EGFR inhibitor Gefitinib (Iressa) while cancer 
cells cultivated in 2D were only weakly affected. In the clinic it could be 
demonstrated that the survival of lung cancer cells in cancer patients was strictly 
dependent on hyperactivated EGFR signaling (oncogene addiction). Moreover we 
could demonstrate that 3D models also exhibited different responses to the 
chemotherapeutic paclitaxel. In this case organotypic cultivation rendered the 3D 
cells more resistant to paclitaxel than in the 2D cultures. We suggest that new drugs 
that could have beneficial effects in vivo might be identified only in 3D model-based 
drug screenings. For the evaluation of drug efficacy within our 3D model, we 
established 3D cell-based assays for the detection of proliferation and apoptosis 
(alamarBlue®, Caspase-Glo® 3/7, Annexin V). We used these assays to evaluate 
drug sensitivity of spheroids generated from four lung cancer cell lines.  
 
Taken together, our data clearly demonstrate that cancer cell physiology and drug 
responsiveness might be clearly different in 2D and 3D cancer models. In the case of 
EGFR signaling only the 3D models exhibited a drug response that was comparable 
to clinical observations in cancer patients (oncogene addiction). However, much 
more work is clearly needed in order to fully exploit organotypic 3D models for basic 
and applied cancer research and personalized medicine.  
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Deutsch| Um potenzielle Defizite von konventioneller Einzelschichtkultur- und Tier-
modellen in der Medikamentenentwicklung zu umgehen, wurden in den letzten Jah-
ren komplexe drei-dimensionale zellbasierte Krebsmodelle entwickelt. Diese dienen 
als ökologische Nische für eine Vielzahl von unterschiedlichen Zelltypen. 3D Modelle 
erlauben es die pathophysiologische Komplexität und Heterogenität von Krebs zu 
imitieren. Daher könnten sie als Basis für robuste und verlässliche in vitro Krebsmo-
delle dienen. In zellbasierten 3D Modellen ist es möglich das geeignete Mikroumfeld 
für viele verschiedene Tumore maßzuschneidern. Nichtsdestotrotz ist noch viel For-
schungsarbeit notwendig, um 3D Modelle in der Pharmaindustrie im Bereich der 
Wirkstoffentwicklung integrieren zu können.  
 
In dieser wissenschaftlichen Arbeit haben wir robuste, standardisierte Methoden 
entwickelt, um 3D Krebsmodelle auf Basis der Tumorsphäroid-Methodik aufzubauen. 
Sphäroide sind sphärische Zellaggregate, welche sich unter definierten experimen-
tellen Kulturbedingungen spontan formen. Da jede Zelllinie individuelle Bedingungen 
benötigt um Sphäroide zu bilden haben wir unterschiedliche Techniken benutzt. Da-
runter befinden sich das „Rotary Cell Culture System“ (RCCS), die „Hanging drop“ 
und die Methylzellulose-basierten Methoden, sowie nicht-adhärente Oberflächen 
(Hydrocell™, poly-HEMA Beschichtung). Aufgrund der Fortschritte auf dem Gebiet 
der Biomaterialien konnten bereits unterschiedliche Matrizen entwickelt werden, die 
in der Lage sind, den eingebetteten Sphäroiden ein maßgeschneidertes Mikroumfeld 
zu bieten. Wir haben Sphäroide in natürlichen (Matrigel™, Collagen Typ 1) und syn-
thetischen (HyStem™, HydroMatrix™) extrazellulären Matrizen (ECM) eingebettet. 
Dies ermöglichte heterotypische Ko-Kulturen, die aus Tumor- und Stromazellen be-
stehen. Des Weiteren wurden menschliche Lungenzellen und primäre Fibroblasten 
stabil transduziert, sodass sie Fluoreszenzproteine exprimierten (EGFP, mCFP, J-
Red). Damit konnten wir zwischen den unterschiedlichen Zelltypen unterscheiden. 
So konnten wir definierte Ko-Kulturen generieren, in welchen es möglich ist, Tumor-
Stroma Interaktionen zu studieren. Dieses Modell ist ein vielversprechendes Werk-
zeug in der Tumorbiologie um die Auswirkungen der Tumor-Stroma Interaktionen auf 
die Medikamentensensitivität zu studieren. Wir haben bereits einen experimentellen 
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Arbeitsablauf für die automatisierte Generierung von Sphäroiden und Organoiden 
(eingebettete Sphäroide) definiert, der für Hochdurchsatz-Screenings (HTS) geeig-
net sein könnte.  
Um die Zellphysiologie von organotypischen 3D Modellen genauer charakterisieren 
zu können, haben wir Affymetrix Gene Chip Analysen durchgeführt. Wir konnten so 
zeigen, dass die organotypische Kultivierung in 3D ECM Matrizen das 
Genexpressionsprofil der Krebszellen wesentlich veränderte. Mithilfe von Phospho-
Proteom Antikörperarrays konnten wir signifikante Veränderungen in der 
Phosphorylierung wichtiger  Proteine zeigen, sobald die Zellen in 3D kultiviert 
wurden. Im Besonderen betraf dies den EGF-(Epidermal Growth Factor) Rezeptor. 
Dieser wurde in den untersuchten Lungenkrebszelllinien, sobald sie drei-dimensional 
kultiviert wurden, hyperphosphoryliert. Dementsprechend sprachen die 3D Modelle 
wesentlich sensitiver auf die Behandlung mit dem EGFR Hemmer Gefitinib (Iressa) 
als Einzelschichtkulturen. In der klinischen Behandlung von Lungenkrebspatienten 
konnte gezeigt werden, dass das Überleben der Krebszellen stark von der 
Hyperaktivität des EGF-Rezeptors abhängig war (oncogene addiction). Weiters 
konnten wir zeigen, dass 3D Modelle ebenso auf das Chemotherapeutikum 
Paclitaxel anders reagierten. In diesem Fall waren die 3D-kultivierten Zellen 
resistenter gegenüber dem Therapeutikum als Einzelschichtkulturen. Daher wäre es 
durchaus denkbar, dass neue wirksame Medikamente nur in 3D-Modell-basierten 
Wirkstoff Screenings ihre günstige Wirkung offenbaren.  
Um die Möglichkeit Therapeutika auf deren Wirksamkeit in den etablierten 3D 
Modellen zu testen, entwickelten wir Protokolle um zellbasierte Assays für Detektion 
von Zellproliferation und Apoptose durchzuführen (alamarBlue®, Caspase-Glo® 3/7, 
Annexin V). Mithilfe dieser Assays bestimmten wir die Medikamentenempfindlichkeit 
von Sphäroiden von vier Lungenkrebszelllinien. 
 
Zusammengefasst konnten wir eindeutig zeigen, dass Zellphysiologie und das 
Ansprechen auf Wirkstoffe in 2D und 3D Krebsmodellen unterschiedlich sein kann. 
Im Falle vom EGFR-Signalweg konnten nur in den 3D Modellen die klinischen 
Beobachtungen bestätigt werden (oncogene addiction). Es sei jedoch darauf 
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hingewiesen, dass noch viel Arbeit nötig ist, um das Potential organotypischer 3D 
Modelle sowohl für die Grundlagen- und angewandte Krebsforschung als auch für 
personalisierte Medizin vollständig ausschöpfen zu können.  
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 Introduction 2
 
 Development of Cancer and Cancer Progression 2.1
Even though more than seventy years have been elapsed since the first use of 
chemotherapeutics, cancer is still second most frequent cause of death worldwide 
accounting for 7.6 million deaths in the year 2008, outranged only by heart diseases. 
This number is predicted to rise to 12 million deaths per year until 2030 according to 
WHO Data and Statistics (New Cancer cases and deaths 2012, Figure 1). It is 
essential to extend our still poor knowledge about the initiation and driving forces of 
cancer in order to functionally understand and treat this complex disease.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In general cancer is a multifactorial disease which is characterized by deregulated 
cell proliferation and dissemination of altered cells in the organism. This is enabled 
by abnormal gene expression and aberrant gene function in these transformed cells. 
Figure 1: New cancer cases and deaths in the USA in 2012. 
The highest cancer incidence rates has prostate cancer in men and breast cancer in women, both accounting for 29% of 
all leading sites followed by lung cancer in both sexes. Nevertheless, lung cancer accounts for more deaths than any 
other cancer type regardless of gender. According to American Cancer Society an estimated 160,340 lung cancer related 
deaths (28% of all cancer deaths) are expected to occur in 2012. 
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All capabilities that a cancer cell acquires being necessary for tumor growth, 
progression, invasion and metastasis can be subsumed as hallmarks of cancer 
(Hanahan D, Weinberg RA, 2000, 2011).  
 
 Sustaining Proliferative Signaling 2.1.1
The probably most fundamental attribute of cancer cells is their ability to sustain 
continuous proliferation by overcoming cellular control elements by e.g. disrupting 
negative feedback mechanisms or up-regulation of growth promoting signals. 
Negative feedback loops are essential in normal tissue to ensure homeostasis of 
intracellular signaling by restraining various types of signaling pathways. Aberrations 
in negative feedback circuitry are frequently found in various malignancies since 
defects in this control element could enhance the proliferative capacity of tumor cells. 
In order to acquire and maintain the proliferative potential the activation of additional 
downstream pathways marks a key event in cancer progression. Homeostasis of cell 
number and tissue architecture is maintained in normal tissues by the controlled 
balance of growth-promoting signals that enable cell growth and cells’ entry and 
progression through the cell cycle. These growth promoting signals are 
predominantly growth factors that bind receptor tyrosine kinase receptors on the cell-
surface e.g. epidermal growth factor receptor (EGFR). In a majority of different 
cancer types sustained proliferation is maintained upon constitutive signaling through 
an activating mutation affecting mitogen-activated protein (MAP)-kinase pathway 
(~40% of human melanomas) and/or hyperactivation of phosphoinositide 3 (PI3)-
kinase pathway (Jiang and Liu, 2009).  
 
 Evading Growth Suppressors 2.1.2
In order to maintain up-regulation of cell growth and proliferation cancer cells 
additionally adopt the ability to evade programs that negatively regulate cell 
proliferation and often depend on two canonical tumor suppressor proteins TP53 and 
RB (retinoblastoma-associated). Furthermore these are key proteins not only in the 
regulation of proliferation but also in the activation of senescence and apoptosis. 
Upon various mainly extra- but also intracellular signals RB functions as a 
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gatekeeper at the G1 to S phase restriction point and decides whether to proceed in 
the cell cycle or trigger senescence or apoptosis program (Burkhart and Sage, 
2008). In contrast TP53 serves as a sensor to various mainly intracellular stress 
conditions and DNA damage and can consequently induce mitotic arrest or if the 
damage is irreparable can trigger apoptosis.  
 
 Resisting Cell Death 2.1.3
Since alteration of cellular circuitry and its resulting opportunity to evade growth 
suppressors, one key feature of cancer is the loss of TP53 tumor suppressor 
function, downregulation of pro-apoptotic factors such as Bax, Bim, and Puma or 
increase of expression of anti-apoptotic factors such as Bcl-2, Bcl-xL (Ren D et al., 
2010). In contrast to apoptosis where the cell shrinks to a small corpse followed by 
its consumption through neighboring cells the necrotic cells increase in size until they 
burst. During this process termed necrosis the cell debris, pro-inflammatory signals 
and bio-active regulatory factors are released into the local tissue microenvironment, 
a feature which is not observed in apoptosis or autophagy. As a consequence 
inflammatory cells of the immune system are recruited during necrotic events which 
can then promote the tumor actively in terms of growth, tumor progression and 
metastasis. More than that, other tumor stroma cells such as cancer-associated 
fibroblasts (CAFs) and cancer-associated macrophages (CAMs) are stimulated by 
the released factors such as interleukins to foster tumorigenesis and to evade cell 
death programs (Hanahan D, Weinberg RA, 2011).  
 
 Enabling Replicative Immortality 2.1.4
Since alteration of cellular circuitry and its resulting opportunity to evade growth 
suppressors, one key feature of cancer is the loss of TP53 tumor suppressor 
function, downregulation of pro-apoptotic factors such as Bax, Bim, and Puma or 
increase of expression of anti-apoptotic factors such as Bcl-2, Bcl-xL (Ren D et al., 
2010). In contrast to apoptosis where the cell shrinks to a small corpse followed by 
its consumption through neighboring cells the necrotic cells increase in size until they 
burst. During this process termed necrosis the cell debris, pro-inflammatory signals 
 Introduction/Development of Cancer and Cancer Progression 
 
Nico Jacobi  19/111 
and bio-active regulatory factors are released into the local tissue microenvironment, 
a feature which is not observed in apoptosis or autophagy. As a consequence 
inflammatory cells of the immune system are recruited during necrotic events which 
can then promote the tumor actively in terms of growth, tumor progression and 
metastasis. More than that, other tumor stroma cells such as cancer-associated 
fibroblasts (CAFs) and cancer-associated macrophages (CAMs) are stimulated by 
the released factors such as interleukins to foster tumorigenesis and to evade cell 
death programs (Hanahan D, Weinberg RA, 2011).  
 
 Inducing Angiogenesis 2.1.5
In order to be provided with sufficient nutrients and oxygen and to ensure 
appropriate removal of toxic metabolites and carbon dioxide a tumor needs 
vasculature. During tumor progression the generation of tumor blood supply is a 
rate-limiting step and therefore exceptionally essential in tumorigenesis. But since 
sufficient oxygen and nutrient supply can only be ensured for cells residing within 
~100-200 µm of vasculature, angiogenesis is often persistently switched in most 
tumors (Dang CV and Semenza GL, 1999). Normally the formation of new blood 
vessels is mainly associated with embryogenesis. Therefore, the tumor must induce 
neovascularization to support tumor growth. This onset of angiogenesis in tumors is 
called the ‘angiogenic switch’ and can occur at any developmental stage during 
tumor progression depending on different varying requirements. It is known that the 
‘angiogenic switch’ is controlled by angiogenesis inducers being mainly receptor 
tyrosine kinase ligands such as vascular endothelial growth factor (VEGF), fibroblast 
growth factors (FGFs), platelet derived growth factor (PDGF) and epidermal growth 
factor (EGF). On the other hand inhibitory molecules such as statins (angiostatin, 
canstatin or endostatin) and Thrombospondin-1 (TSP-1) counter angiogenesis by 
arresting an endothelial cell in a quiescent state (Bergers B and Benjamin LE, 2002). 
Due to an acquired imbalance of these mediators in the tumor the ‘angiogenic 
switch’ is kept at ‘on’-position. Hence the tumor’s blood supply allows tumor growth 
to proceed and ultimately also serves as a prerequisite for the onset of cancer 
metastasis.  
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 Activating Invasion and Metastasis 2.1.6
A key moment of tumorigenesis is invasion and metastasis which is a multistage 
process during which malignant cells enter vasculature and spread from the primary 
tumor to distant sites in the body where they proliferate and form new tumor foci 
(Talmadge JE and Fidler IJ, 2010; Poste G and Fidler IJ, 1980; Figure 2A). Stephen 
Paget’s 1889 proposal on the ‘Seed and Soil Hypothesis’ exemplified that the 
process of invasion and metastasis is dependent on both, immanent properties of 
the tumor cells and of the host response. This suggests that invasion and metastasis 
are not stochastic events but a complex sequence of events. Consequently 
metastasis is highly susceptible to any interference ultimately resulting in failure of 
forming secondary tumors. For this purpose carcinoma cells can exploit a 
multifaceted regulatory program termed epithelial-mesenchymal transition (EMT) to 
acquire attributes enabling invasion, apoptosis resistance and dissemination. EMT is 
governed by highly conserved effector molecules (Figure 2B) such as Wnts, 
fibroblast growth factors (FGFs), snails, Zeb1/2 and E-cadherin (Eger et al., 2004, 
2005). The latter is known to be a master regulator maintaining adherens junctions, 
tight junctions and desmosomes of fully polarized epithelial cells and hence their 
basolateral and apical orientation. These cell-cell contacts impede the motility of 
normal epithelial cells. During the EMT program these epithelial markers are 
downregulated in concomitance with up-regulation of mesenchymal markers such as 
fibronectin, vimentin or smooth-muscle actin (Aigner K et al., 2007). The resulting 
phenotype acquires mesenchymal gene-expression patterns and properties which 
enable invasion into the tissue and blood stream and ultimately to form secondary 
tumor foci more efficiently (Thiery JP and Sleeman JP, 2006; Eger A and Mikulits W, 
2005).  
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Nevertheless at the site of metastasis carcinoma cells are then confronted with the 
absence of continuous signaling of EMT effectors which formerly triggered and 
maintained EMT at the primary tumor site. This may drive mesenchymal-epithelial 
transition (MET), a reciprocal program during which the expression of epithelial 
markers reconvenes resulting in the reversion of the cancer cells to a noninvasive 
state (Hanahan D, Weinberg RA, 2011).  
A B 
The Cycle of Epithelial Plasticity 
Figure 2: A| The Invasion-metastasis cascade.  
Metastasis is a multistage process in which cancer cells disseminate from the primary tumor to form secondary tumor foci 
at the same or distant organs. This process consists of the sequential steps of local invasion into tissue, intravasation into 
blood vessels, survival in the circulation, extravasation from blood vessels into the tissue and colonization in other organ 
environments. Each selective step is potentially rate limiting and comprises stochastic elements which ultimately could 
impede or prevent completion of metastasis.  
B| The cycle of epithelial-mesenchymal transition and its reciprocal process of mesenchymal-epithelial transition.  
In this diagram the high plasticity of epithelial cells is depicted. Often during the initiation of metastasis carcinoma cells 
exploit the regulatory program of epithelial-mesenchymal transition (EMT) to gain cell motility which facilitate the evasion 
from the primary tumor. EMT and its reversed process are regulated by EMT and MET effetors respectively. A key event 
during EMT and MET is the regulation of cell-cell and cell-substrate anchors such as tight junctions, adherens junctions 
and desomosomes. ECM, extracellular matrix; FGFR2, fibroblast-growth-factor receptor-2; FSP1, fibroblast-specific 
protein-1; MFs, microfilaments.  
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This only outlined a number of the multifarious aberrations which result in 
disturbances of homeostasis paving the way for more than 100 distinct types and 
subtypes of cancer known today (Hanahan D, Weinberg RA, 2000). The path of cells 
on the way to malignancy can vary substantially which is reflected by the fact that 
histologically identical tumors may comprise completely different subsets of 
mutations. As a consequence the development of new potent anti-cancer therapies 
for a broad range of different cancer types is a challenging mission. Nevertheless, it 
is a straightforward approach to target the acquired cancer hallmarks in order to 
interfere with tumor growth and progression. An outline of potential anti-cancer 
agents which interfere with the cancer capabilities is depicted in Figure 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Examples of drugs targeting hallmark capabilites acquired by cancer cells during 
tumorigenesis.  
Due to fact that the cancer hallmark capabilities are required for tumor growth, progression, invasion 
and metastasis they serve as logical targets for anti-cancer drugs. Therefore several drugs targeting 
these hallmarks have been developed or are already in clinical use and show promising potential. 
Picture by Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: The next generation. 
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 Drug Discovery  2.2
 
 Early Stages  2.2.1
Early Stages  
Historically, pharmacological studies relied exclusively on animal tests to provide 
reliable indications of drug efficacy and safety. In 1959, William M. S. Russel and 
Rex L. Burch, two English scientists, carried out a study in which they systematically 
gathered data on animal experimentation. Upon their investigations Russel and 
Burch defined ethical aspects for the “development and progress of humane 
techniques in the laboratory” and initiated the 3Rs movement to Replace, Reduce 
and Refine the use of animals in experimentation (Russel WMS and Burch RL, 
1959). Due to strong international support for the 3Rs movement the focus was 
shifted from animal testing to the development of alternative in vitro techniques. 
Since 1996 the 3Rs are referenced in the “Guide for the Care and Use of Laboratory 
Animals” a 140-page document issued by the National Academy Press. The 3Rs 
movement paved the way for cell-based ex vivo drug discovery and soon the 
remarkable advantages of cell-based assays i.e. predictability, reproducibility, 
possibility of automation, reduction of costs and miniaturization implied that this tool 
is even more than an alternative to in vivo studies in early stages of drug discovery 
process. The large portfolio of cell-based assays includes a variety of assays that 
measure cell proliferation, toxicity, motility/invasiveness, activation of specific 
signaling pathways and changes in morphology (Michelini E et al., 2010). Due to 
their versatility these assays can be used in the drug discovery of various diseases. 
 
 Cancer Drug Discovery 2.2.2
A primary area of contemporary medical research is the discovery and development 
of new anti-cancer drugs. Several promising approaches such as targeted therapies, 
nanotechnology or gene therapy have been developed in the last decades to fight 
this heterogeneous disease. In 2008 more than 800 new anti-cancer agents were in 
phase I clinical trials certainly raising hopes to cure cancer. Nevertheless, anti-
 Introduction/Drug Discovery 
 
 
Nico Jacobi  24/111 
cancer drug discovery in particular is fraught with obstacles such as lack of efficacy 
and safety of the drug. Due to that only ~10 percent of those 800 new anti-cancer 
agents will master the rocky road to registration and clinical utility, an expensefull 
and more than a decade lasting endeavor with costs of US$1 billion.  
 
From Drug Target to Clinical Candidate| The modern anti-cancer drug discovery 
process is the interplay between various disciplines including genetics, genomics 
and bioinformatics, cell and molecular biology, structural biology, pharmacology, 
pharmacokinetics and metabolism, medicinal chemistry, and experimental medicine 
(Neidle S, 2008). A typical anti-cancer drug discovery cascade is depicted in  
Figure 4.  
 
 
 
 
 
 
 
 
 
 
Starting from initial target identification and validation in biochemical screening 
assays (millions of compounds) using HTS a lead compound is being identified. The 
subsequent target modulation due to the desired cellular effect such as induction of 
apoptosis or growth inhibition is assessed in vitro using well characterized cell lines. 
Using high-throughput campaigns at this stage the ADME (i.e. absorption, 
distribution, metabolism, and elimination) properties of the investigational drug can 
be predicted for following in vivo tests. In order to give a profound prediction for the 
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Figure 4: The drug discovery process.  
Identifying and devloping a potent drug is a process of sequential phases during which the candidate compounds are 
tested for their specific activity in a certain therapeutical context. During this process the number of drug candidates is 
continuously decreasing from many thousands of compounds (target identification) down to a few remnants in the 
preclinical and clinical development. The lack of bioavailability, efficacy and safety of drug candidates are the main 
reasons for the high attrition rates during the drug discovery process. Optimization of drug developmental processes 
including the establishment of better predictive models is therefore crucial for the reduction of failure rates in modern drug 
discovery. Only then the time for development of a highly potent drug and its associated costs of ~US$1 billion could be 
reduced.  
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drug’s ability to traverse cell membranes, pKa, lipophilicity and aqueous solubility is 
determined. Thereafter, the demonstration of anti-cancer efficacy at atoxic doses of 
a few dozens of compounds is performed in animal studies. Prior to pre-clinical trials 
the evaluation on toxicology, manufacture and formulation are carried out in one 
rodent and one non-rodent species.  
 
As depicted in Figure 4, a vast majority of new investigational drugs (NID) are 
already predestinated to fail in its infancy. In order to reduce high drop-out rates of 
NID Lipinski’s ‘rule of 5’ is commonly considered in very early stages of drug 
discovery (Lipinski CA et al., 2001). This rule was derived from analyses showing 
that 90 percent of orally absorbed drugs had certain physical characteristics:  
 
• Molecular weight smaller than 500 Da  
• An octanol-water partition coefficient (lipophilicity) smaller than 5  
• Fewer than 5 hydrogen-bond donors  
• Less than 10 hydrogen-bond acceptors  
 
Since orally absorbable drugs are generally preferred it is very common that 
screening libraries contain many compounds that obey the “rule of 5”. Therapeutics 
which are exceptions to Lipinski’s rule are e.g. antibiotics and cardiac glycosides 
since they are compound classes that are substrates for biological transporters 
(Lipinski CA et al., 2001).  
 
In the past decades the discovery and validation of new anti-cancer drugs in 
preclinical studies was limited by the fact that most conventional cancer models did 
not faithfully recapitulate the complex disease ex vivo. In most cases cancer cell 
lines (e.g. NCI60 & CMT1000 platforms) or primary cancer cells that were isolated 
from whole tumor samples were simply propagated on two-dimensional (2D) 
synthetic substrata such as glass or plastic that force cells to adjust to artificially flat 
and rigid surfaces. Due to those conditions they lacked essential properties found in 
vivo (e.g. response of the three-dimensional microenvironment present in tissues) 
 Introduction/Drug Discovery 
 
 
Nico Jacobi  26/111 
and hence failed to serve as reliable predictors of drug efficacy prior to animal testing 
(Sharma SV et al., 2010). Therefore there is the necessity for alternative testing 
methods and innovative models including cell aggregates and tissue slices which 
recapitulate the complex pathophysiology of cancer more reliable in vitro.  
Tissue engineering, the establishment of artificial multicomponent three-dimensional 
tissues, approaches the in vivo situation where 2D cell culture fails and hence may 
be a powerful tool for modern drug screening campaigns. These cell based 
surrogates can comprise organ-specific properties and therefore may serve as a 
suitable ecological niche for individual cell types. The artificial tissue surrogates 
could be used for studying disease pathogenesis and developing new in vitro assays 
for anti-cancer drug screening (Bhadriraju K et al., 2002).  
 
At present in vitro generated microtumors that consist of several cell types and that 
are embedded in different extracellular matrices (ECM) might serve as novel and 
innovative drug discovery models. They might span the gap between 2D cultures 
and in vivo studies to screen for new anti-cancer drugs. The engineered microtumors 
mimic the complex pathology of cancer more closely and consequently may predict 
in vivo drug efficacy more reliable than 2D cultures.  
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 Cell-based Assays in Drug Discovery  2.3
 
To exploit the full potential of the above depicted in vitro models to evaluate the 
pharmacology of candidate anti-cancer agents a large panel of cell-based assays 
has been developed. It is more than 60 years now since the first human cancer cell 
line (HeLa) was developed at Johns Hopkins Medicine (Baltimore, Maryland, USA). 
HeLa cells marked the beginning of established cell lines and enabled the 
development of drugs against numerous diseases (Lucey BP et al., 2009). Today a 
large panel of easy-to-cultivate immortalized cell lines is available with cell history, 
growth behavior and genomic information provided from a multitude of repositories 
such as the American Type Culture Collection (ATCC). Therefore these 
characterized human tumor-derived cell lines serve as ideal candidates for functional 
screens in anti-cancer drug discovery.  
 
 
 NCI60 and CMT1000 Cell Line Panels  2.3.1
The development of the first high-throughput cancer cell line screening program of its 
kind the US National Cancer Institute 60 anti-cancer drug screen (NCI60) started in 
1986 (Figure 5). The 60 cell lines constituting this panel were selected due to various 
features including acceptable growth characteristics and sterility (Shoemaker RH et 
al., 2006). Cell-based assays, miniaturization in the form of microtiter plates and 
automated liquid handling is largely attributable to this scientific achievement whose 
development and operation has spanned over 20 years. In the late 80s and 90s of 
the last century 60 different cancer cell lines seemed to be an adequate number 
comprising the NCI60 panel. The reason for that was that the cancer treatments 
using predominantly nonspecific cytotoxic agents resulted in high rates of clinical 
responses. It was suggested that 6-9 human tumor-derived cell line representatives 
for each type of cancer would be sufficient to estimate the individual drug response 
(Shoemaker RH et al., 2006; Sharma SV et al., 2010). Nevertheless, the clinical 
activity of modern targeted anti-cancer agents is often limited to only a small 
subgroup of patients which ultimately indicated the need for larger cell panels. The 
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CMT1000 platform, launched in 2006, included 1.200 cell lines in the year 2010. By 
using this cancer cell line-based screening platform it was possible to demonstrate 
that the clinical responses to targeted inhibitors could be traced back to genomic 
aberrations to a remarkable degree (Sharma SV et al., 2010). This finding indicates 
the necessity of cell-based in vitro assays in the drug discovery process.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 High-throughput Screening (HTS) and High-content Screening (HCS)  2.3.2
Due to the multiplicity of detection technologies that have been developed in the past 
decades the potent discipline of cell-based high-throughput screening (HTS) could 
be established around 1990. In these campaigns large libraries of around 100,000 to 
2 million differently small molecules are screened to allow the generation of lead 
compounds against specific molecular targets in cancer cells (e.g. kinases, 
receptors, transporters). Prior to 1989 it was virtually unfeasible to screen this 
tremendous number of compounds for their biological activity. Combined with the 
rapid progress in molecular genetics (e.g. expression of receptor subtypes in cells 
normally lacking their expression) and the general advantages of in vitro assays (i.e. 
predictability, reproducibility, possibility of automation) HTS campaigns are 
straightforward tools in modern pharmaceutical industry (Lipinski CA et al., 2001).  
Figure 5: History of the development of cell-line platforms for evaluating anti-cancer agents.  
Since decades the notable success of anti-cancer drug discovery and development is highly dependent on human tumor-
derived cell line platforms such as NCI60 and the recently launched CMT1000. Picture by Sharma SV et al., 2010, Nature 
Reviews Cancer (10):241-253.  
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In order to exploit the inherent capabilities of HTS various automated systems have 
been developed. The Array Scan® (Cellomics, Pittsburgh, PA, USA) was the first 
system which integrated microscopy, digital imaging and data processing within a 
single platform (Giuliano KA, 1997). This versatile imaging platform was designed for 
high capacity analyses (high content screening, HCS) for drug discovery campaigns 
using cellular assays in 96- and 384-well plates. By using fluorescent probes (i.e. 
antibodies chemically coupled to low-molecular-weight fluorogenic dyes; fluorogenic 
proteins such as GFP genetically fused to desired cellular target) for HCS it is 
possible to measure a multitude of cellular features at once. The obtained data can 
deliver solutions for target validation and lead optimization and therefore improve the 
drug development process. Nevertheless, while low-molecular-weight dyes coupled 
to proteins fail to visualize intracellular targets (inability to enter living cells) the use 
of reporter proteins has certain limitations, as well. The high molecular mass of 
fluorogenic proteins can promote aggregation which subsequently leads to a quench 
of fluorescent signal. Therefore, instead of using fluorogenic proteins also synthetic 
membrane-permeable fluorophores (e.g. 4′,5′-bis(1,3,2-dithioarsolan-2-yl)fluorescein) 
are used. When these fluorophores encounter a specific recombinantly expressed 
protein in the target cell it binds to it and starts to fluoresce (Griffin BA et al., 1998).  
This was only an outline of how data for drug discovery studies are assessed in HTS 
today. The portfolio of assays to evaluate a new investigational drug (NID) is virtually 
inexhaustible today.  
 
 Cell-based Assays 2.3.3
The development of rapid, reliable and cost-efficient high-throughput screening 
assays is of substantial importance during the process of drug discovery and 
development. By exploiting the large portfolio of cell-based assays in the very early 
stages of drug discovery data about the drug-candidate leads’ biological activity, 
toxicological profile, biochemical mechanisms, and off-target interactions can be 
assessed. Recently, cell-based screening methods were used to evaluate drug 
related effects on several target classes such as G protein-coupled receptors 
(GPCR), ion channels and transporters, kinases and phosphatases, as well as 
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nuclear transcription factors (Michelini E et al., 2010). The therapeutic efficacy of a 
candidate anti-cancer agent can be evaluated by the means of its ability to induce 
the reversion of the acquired cancer hallmark capabilities i.e. sustaining proliferative 
signaling, evading growth suppressors, resisting cell death, enabling replicative 
immortality, inducing angiogenesis, activating invasion and metastasis (Figure 3). 
Hence a large panel of different cell-based in vitro assays has been established in 
the past.  
 
Apoptosis Assays| Due to functional studies it is commonly accepted that 
apoptosis, the process of programmed cell death, serves as a natural barrier to 
tumorigenesis since it is a regulatory program to ensure tissue homeostasis (Lowe et 
al., 2004). The uncontrolled proliferation of cancer cells can be maintained by 
bypassing apoptosis. This is often achieved due to mutations found in apoptosis 
related circuitry and relaying proteins such as TP53, Bcl-2, Bcl-xL Bax, Bim, Puma 
(Hanahan D, Weinberg RA, 2000, 2011). Therefore this circuitry is a target for many 
anti-cancer drugs in order to regain command over the apoptosis machinery and 
hence to induce apoptosis in cancer cells ultimately. Apoptosis assays in which 
apoptotic cells can be quantified accurately are therefore of prime importance in 
order to evaluate the efficacy of a candidate anti-cancer drug (Berg et al., 2007). Due 
to that a large panel of cell-based apoptosis assays is available today which ideally 
quantify apoptotic cells rapidly, reliable, safe, sensitive, simple and cost efficient 
(O’Brien J et al., 2000).  
 
Since both, the intrinsic (cytochrome C) and the extrinsic (Fas-associated Death 
Domain, FADD) apoptotic pathway ultimately culminates in the activation of 
apoptosis-associated proteases called caspases a common target to quantify 
apoptotic cells are caspases (commonly caspase-3, 7, 8, and 9, Alberts et al., 2008). 
Since caspases, or cysteine-aspartic-proteases, this feature is commonly utilized in 
apoptosis assays to determine apoptotic events. For this many apoptosis assays use 
compounds that are cleaved by caspases. These compounds are conjugated with a 
detectable molecule to assess data colorimetrically, luminometrically or 
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fluorometrically. Commonly used apoptosis assays are Promega’s CytoTox-Fluor™ 
cytotoxicity assay which detects minute amounts of extracellular caspase activities 
fluorometrically and Promega’s Caspase-Glo® 3/7 assay which luminometrically 
(luciferase) detects caspase 3/7 activity in a cell lysate. Both assays can be 
multiplexed to measure more than one parameter per well at once (acc. to Promega, 
Mannheim, Germany).  
 
Another possibility to determine apoptotic events is the apoptosis associated switch 
of phosphatidylserine (PS) from the inner to the outer leaflet of the cell membrane. 
Under non-apoptotic conditions PS is exclusively located in the inner leaflet of the 
membrane. In the early stages of the apoptotic program PS is exposed on the outer 
leaflet as a result of decreased aminophospholipid translocase activity and activation 
of a calcium-dependent scramblase. In a physiological context this exposure is 
important for phagocytes to recognize and remove apoptotic cells (Fadok VA et al., 
1998). Since Annexin V, a human vascular Ca2+ dependent anti-coagulant, 
possesses a high affinity for PS it can be utilized to detect these early events of 
apoptosis (Andree HAM et al., 1990). For the detection of translocated PS Annexin V 
is linked to fluorophores such as fluorescein isothiocyanate (FITC). In fact the PS 
translocation is not unique to apoptosis but can also be observed during necrosis. In 
order to distinguish between necrosis and apoptosis using the Annexin V system a 
dye exclusion test is therefore performed additionally. While during the initial stages 
of apoptosis the cell membrane stays intact it loses its integrity during necrosis 
(Vermes I et al., 1995; Engeland v. M, 1998). Hence if the dye is exclusively 
detectable on the cell’s exterior the cell can be considered as apoptotic and not 
necrotic.  
 
Cell Viability and Cytotoxicity Assays| Since cell viability, cell vitality and 
compound cytotoxicity are key characteristics in the drug evaluation a large panel of 
cell viability and cytotoxicity assays are available from a multitude of companies. The 
ideal in vitro test to assess cell viability and cytotoxicity must be rapid, reliable, safe, 
sensitive, simple and economical. Furthermore, since these assays are used to 
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assess drug efficacy of NIDs the assay must not interfere with the candidate drug. 
(O’Brien J et al., 2000). Generally speaking there are conventional reporter-based 
cell assays and cell-based label free approaches. Using reporter-based cell assays 
can generate artifacts due to genetic alterations of the cells or the reporter-protein 
related disturbances of the target signaling pathways. Since labeling can alter cell 
physiology and hence sensitivity to certain potential drugs label-free assay might 
predict drug efficacy more reliable than reporter-based cellular assays (Abbit KB et 
al., 2000).  
 
One possible means of assessing cell viability in a label-free approach is to 
determine the ATP content present in the cells. Almost all cellular processes which 
require energy utilize the potential of ATP as energy source; consequently the 
amount of ATP in a metabolically active cell correlates with its viability. ATP is 
exclusively generated during mitochondrial processes. The production of ATP is 
stopped within minutes after the loss of membrane integrity (i.e. apoptosis and 
necrosis) and the actual ATP level present in the cell is reduced sharply due to 
endogenous ATPases. By utilizing bioluminescence the amount of ATP can be 
quantified very rapidly. The luciferase system (e.g. CellTiter-Glo®, Promega) requires 
ATP and luciferin as substrates to generate bioluminescent light directly proportional 
to the amount of ATP present. An inherent limitation of common luciferase assays is 
the short half-life of the luminescent emission due to the degradation of ATP by 
ATPases. This can be overcome by pH dependent inactivation of ATPases or by 
adding ATPase inhibitors. Additionally candidate drug compounds may also interfere 
with the firefly luciferase resulting ultimately in false positives. Promega’s CellTiter-
Glo® system therefore utilizes a proprietary Ultra-Glo™ rLuciferase, which is less 
sensitive to compound related inhibition (Hook B and Schagat T, 2011).  
 
A second target for the determination of cell viability is the respiratory chain and its 
underlying oxidative phosphorylation. Since oxidative phosphorylation involves the 
transport of electrons via several membrane proteins of the mitochondrium many 
reduction-oxidation (redox) reactions are involved. This fact can be used to monitor 
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cell viability due to the reducing power of metabolically active cells to convert 
substances such as alamarBlue® (Life Technologies) to a fluorescent molecule by 
chemical reduction (O’Brien J et al., 2000). The active ingredient of alamarBlue® is 
resazurin (Figure 6), a nontoxic, cell permeable bluish compound that is reduced to 
resorufin in viable cells producing red fluorescence (according to Life Technologies, 
O’Brien J et al., 2000). This fluorescent signal is direct proportional to the number of 
living cells and upon excitation at 570 nm the fluorescence peak emission is 
detected at 585 nm. Additionally, alamarBlue® can also be detected via absorbance 
at 570 nm which lowers sensitivity of the measurements. Despite its simplicity, some 
drawbacks to the routine use of alamarBlue® were observed. First the accumulation 
of resorufin was shown in tests with several toxicants such as 0,3-1mM nickel 
chloride which ultimately could result in an overestimation of cell number. Second 
the continuous reduction of resorufin produces hydroresorufin, a colorless and non-
fluorescent molecule. This over-reduction which is due to high metabolic rates of 
certain cell types leads to an underestimation of cell viability and metabolic activity. 
This ultimately could lead to artifactual results and misinterpretations in drug 
evaluation (O’Brien J et al., 2000).  
 
 
 
 
 
 
 
 
 
 
 
 
Senescence Assays| Normal somatic cells do not replicate indefinitely but enter 
cellular or replicative senescence after a defined number of cell divisions. This 
Reduction 
Figure 6: Chemical reduction is the mechanism of alamarBlue® as an indicator for cell viability.  
Resazurin, a non-fluorescent molecule is converted by means of the redox potential of the respiratory chain in living cells. 
The resulting resofurin is a red-fluorescent molecule which can be measured and correlated with viability of a cell popula-
tion. Modified picture by O’Brien J et al., European journal of biochemistry/FEBS, 2000. 
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process is the underlying cause of aging. Furthermore, this is of prime importance 
since immortality of cells increases the susceptibility to malignant transformation. 
Hence the process of senescence is thought to be an important mechanism to avoid 
tumorigenesis (Dimri GP et al., 1995).  
 
Senescence-associated β-galactosidase (SA-β-Gal) is an enzyme that is expressed 
in cells originating from all three germ layers. It is probably the most commonly used 
indicator for senescence. Since SA-β-Gal is expressed only in senescent cells, pre-
senescent, quiescent or immortal cells are negative for SA-β-Gal. The enzymatic 
activity of SA-β-Gal can be utilized to determine senescence. X-gal, a substrate of β-
galactosidase, is converted by β-galactosidase to a bluish measurable precipitate. 
Therefore the presence of β-galactosidase can be assessed using this characteristic. 
Nevertheless, in order to detect the presence of SA-β-Gal a biological characteristic 
of SA-β-Gal can be exploited. At pH 6.0 only SA-β-Gal is active while lysosomal β-
Gal (expressed in most cells) shows optimal activity at pH 4.0. Therefore, if the 
senescence assay is performed at pH 6.0 only senescent cells are stained blue 
(Dimri GP et al., 1995). This finally allows for determining the effect of the candidate 
drug on senescence.  
 
Hypoxia Assays| As discussed previously in order to assure the supply with 
sufficient nutrients and oxygen the cells must reside within ~100-200 µm of 
vasculature. To maintain the state of sufficient oxygen supply (normoxia) is not only 
essential for normal but even more for highly proliferative malignant tissue. Regularly 
a tumor faces a state of diminished tissue oxygen tension during tumorigenesis, a 
state that is called hypoxia, since tumor growth may even outpace angiogenesis. For 
this purpose cells have intrinsic ways such as reduction of energy consumption and 
anaerobic metabolism to withstand the resulting fluctuations in oxygen supply 
(Simon MC, 2010). Cancer cells could utilize inherent programs to adapt to hypoxic 
environments and to avoid hypoxia induced cell death. More than that, it was issued 
that the probability of invasion and metastasis are positively correlated with the 
degree of intratumoral hypoxia since undersupply with oxygen and nutrients may 
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force cancer cells to get access to distant vasculature (Zhong H et al., 1999). Many 
genes are differentially regulated during these programs that finally govern 
angiogenesis, metabolism and cell survival. Hypoxia inducible factors 1,2 (HIF-1 and 
HIF-2) are transcription factors that play a central role in these phenotypic shifts of 
the cells (Simon MC, 2010). It was shown that HIF-1α is highly overexpressed in a 
broad range of cancers upon exposure to hypoxic conditions (Zhong H et al., 1999). 
Giving an example the expression of vascular endothelial growth factor (VEGF) and 
the glucose transporter 3 (GLUT-3) is up-regulated by HIFs. The angiogenic VEGF is 
of prime importance in the formation of blood vessels de novo (neovascularization). 
Blood and therefore oxygen supply might be assured within the malignant tissue by 
up-regulating the expression of VEGF. Nevertheless, it was reported that the 
vasculature formed by this tumor-induced process is often inadequate due to its 
rather leaky and defective structure and may not supply the tumor with nutrients. As 
a consequence even vascularized tumors could comprise hypoxic areas in which the 
HIF induced programs are up-regulated. Moreover, due to the increased expression 
of GLUT-3 the glucose influx into the cells is enhanced. This results in the production 
of sufficient amounts of ATP by the anaerobic glycolysis. The ability to induce 
angiogenesis and the HIF-induced programs are potential targets for anti-cancer 
drugs. Common assays to determine HIF-1 presence in cell lysates are sandwich 
ELISAs such as the HIF1α EZ-TFA Transcription Factor Assay (EMD Millipore) 
which enables chemiluminescent detection.  
 
 
Proteome Analysis using Post-Translational Modification Assays| After 
transcription and translation the majority of proteins do not have their final structure 
after they emerge from the ribosomal biosynthesis machinery. It is known that a set 
of more than 30 different modifications can alter amino acid residues of proteins by 
proteolytic cleavage or addition of a modifying group. These post-translational 
modifications (PTMs) are essential since they may determine the protein’s activity, 
state, localization, turnover, and interactions with other proteins. Consequently, 
PTMs are essential to regulate signaling pathways of which many of those are in key 
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positions of regulating certain aspects of cell behavior such as proliferation and cell 
survival (Alberts B et al., 2008; Mann M and Jensen ON, 2003).  
Phosphorylation represents a frequent PTM and plays among others a central role in 
tumorigenesis. In our genetic repertoire hundreds of protein kinases and 
phosphatases are known to modify proteins on serine, threonine, or tyrosine amino 
acid side chains thereby generating a multitude of protein molecular variants (Walsh 
C, 2006). This reversible modification represents a molecular switch for the 
activation/inactivation of enzyme activity, modulation of molecular interactions and 
signaling, which may ultimately regulate proliferation, cell survival and tumorigenesis 
(Mann M and Jensen ON, 2003). For this purpose it is essential to determine the 
phosphorylation patterns of certain protein panels known to be involved in 
tumorigenesis. This would allow unraveling the complexity of tumor-associated 
signaling and its underlying mechanisms cancer cells could exploit to evade anti-
cancer treatments and ultimately to identify new anti-cancer drug targets.  
 
A convenient method to detect changes in phosphorylation of multiple crucial 
proteins at once is the Proteome Profiler Antibody Array™ (R&D Systems®, 
Abingdon, Oxon, UK). The underlying protein array technology allows for screening 
of more than 40 different phosphorylated proteins in a micro-array like approach. 
This profiling is enabled by highly sensitive antibodies which are directed against 
specific phosphorylation patterns of certain target proteins. The underlying 
methodology is similar to a sandwiched western blot where the capture antibodies 
are spotted on a nitrocellulose membrane. After binding the respective protein (in a 
lysate sample) a detection antibody conjugated with horseradish peroxidase (HRP) 
sensitive to phosphoproteins binds to the complex. Bioluminescence-based readout 
allows for highly sensitive detection of changes in phosphorylation patterns of the 
investigated samples (R&D Systems, 2011).  
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 Engineering of Pathological Tissues for Anti-Cancer Drug Dis-2.4
covery  
 
In vivo, cells and extracellular matrix (ECM) form tissues, which join together in the 
structural and functional units of organs that communicate with each other and are 
interlinked by vasculature to ultimately form a complex organism (Egeblad M, 2010). 
Consequently, the organ’s function can be traced back to the activity of specialized 
cells in a complex network. The stroma consists of extracellular macromolecules 
(proteoglycans, hyaluronic acid, fibronectin, collagen and laminin) constituting the 
extracellular matrix (ECM) and various types of stromal cells. The stromal cells 
include fibroblasts, adipocytes, cells of the vascular and the immune system. It was 
once thought that the ECM serves primarily as a framework which stabilizes the 
tissues. Today it is commonly accepted that this scaffold even can regulate cell 
morphology, differentiation, proliferation and cell survival to outline just a few (Alberts 
B et al., 2002). Even though many advances have been produced by standard two-
dimensional cell culture studies data from more physiological 3D cultivation 
approaches show the critical impact of three-dimensionality on cells and hence 
evaluation of drug efficacy. Due to the properties of the ECM to determine a cell’s 
fate it seems apparent that the specific cellular and matrix microenvironment 
provided to cells would have a crucial impact on the sensitivity of cells towards drug 
application. Hence 3D cultures are currently being exploited in many studies 
focusing on invasion/metastasis, angiogenesis, tissue modeling and remodeling, and 
might be highly predictive models in drug discovery in the near future.  
 
 Commonly Used In Vitro 3D Models 2.4.1
Basically there are two different approaches to establish in vitro 3D organotypic 
models for a multitude of different studies. In the first approach whole tissue samples 
are harvested in vivo for subsequent cultivation in vitro. Second the 3D models are 
established using isolated cells from already established cell lines or dissociated 
tissues (Yamada KM and Cukierman E, 2007). 
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Ex vivo tissue explants as in vitro models| Since tissues have a unique and highly 
complex 3D architecture ex vivo tissue explants serve as a promising source for 3D 
in vitro models to study diseases and their underlying molecular mechanisms. Since 
these explants comprise a heterologous context of several different cell types 3D in 
vitro co-culture models can be used to reveal unknown cell-cell and cell-ECM 
interactions, and their related control mechanisms that regulate cellular 
differentiation, proliferation and apoptosis (Kim JB, 2005). Since these are key 
characteristics in evaluating pharmacological properties of novel anti-cancer drugs 
these models are promising tools in modern drug discovery. Hypoxia and nutrient 
insufficiency are reported to be present in most tumors in vivo with a size beyond 
several mm3 which ultimately could result in necrosis (Dang VC and Semenza GL, 
1999). Normal and transformed cells utilize inherent programs to avoid hypoxia 
induced cell death and to adapt to these hostile environments. Hence tumor biology 
could benefit from these 3D tissue models to study the induction of angiogenesis and 
resistance to anti-cancer drugs ex vivo (Hicks KO et al., 2006). As discussed 
previously vasculature is essential for tissue maintenance since sufficient oxygen 
and nutrient supply can only be ensured for cells residing within ~100-200 µm 
around blood vessels. Only recently, promising approaches were reported to 
generate blood vessels in vitro using embryonic stem cells (ESCs) (Kreuger J et al., 
2006; Jakobsson L et al., 2007). Nevertheless, generating functional vasculature in 
in vitro 3D tumor models is more than a challenging mission which definitely will be a 
focus in future tissue modeling studies. In order to maintain the tissues under 
normoxic conditions the harvested viable tissues are sliced in ~0.1-0.3 mm thin 
slices prior to further cultivation. This approach is facilitated by using specialized 
devices such as microtomes (e.g. Krumdieck, Alabama Research and Development 
Corp., Munsford, USA), or more recently vibratomes (e.g. Leica VT1200 S, Leica 
Microsystems, Wetzlar, Germany). These instruments allow for gentle treatment of 
the samples to ensure the generation of highly viable tissue slices (van der Kuip H et 
al., 2006; Zimmermann M et al., 2009). Subsequently the thin slices can be 
cultivated then either on organotypic supports (such as Teflon membranes with 0.4-
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µm pores, Millipore) and submerged in serum-supplemented specific media or are 
embedded into ECM scaffolds (Vaira V et al., 2010).  
Despite its potential the inherent limitation of this approach is its transitory nature 
which allows basically only relatively short term culture. In addition, to ensure viability 
of tissue slices the harvested tissues (residual tissue not needed for diagnostic 
purposes) must be transported from the operating rooms to the laboratory within the 
shortest time period possible (~30 min, Gramignoli R, 2011). The collection of human 
tissues for research and drug discovery studies must follow ethical and institutional 
guidelines (informed consent).  
In addition, predicting the response of an individual patient to a certain anti-cancer 
therapy, i.e. personalized medicine, is of paramount importance. Ex vivo tissue 
explants might be a promising approach to evaluate the pharmacological properties 
of anti-cancer drugs related to the individual cancer patient by using in high-content 
phenotype based drug discovery (Vaira V et al., 2010).  
 
In vitro models established from isolated cells| In a second approach to establish 
in vitro 3D organotypic models isolated cells are used instead of whole tissue 
samples. These cells originate either from cell lines, dissociated primary tissues or 
stem cells. After the isolation the cells are propagated in vitro prior to embedding as 
single cells or cell aggregates in natural (Matrigel™, fibronectin, collagen, laminin) or 
synthetic (Extracell™, self-assembling peptide nanofibers) ECM scaffolds. Since in 
these models the cells attach to surrounding macromolecules of the ECM rather than 
to two-dimensional coated surfaces, matrix composition and rigidity have crucial 
influence on cell signaling and cell behavior (Cukierman E et al., 2002). As a logical 
consequence the drug response of cells cultured in three dimensions might be 
completely different compared to cells cultured on conventional two-dimensional 
coated surfaces.  
Another important aspect of physiological niches is the presence of stromal cells 
which is known to be a crucial feature in the early stages of cancer metastasis. For 
anti-cancer drug discovery studies it is therefore essential to provide the tumor with 
stromal cells in order to evaluate the drug’s pharmacological properties more 
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reliable. For this, due to the ability of malignant cells to form spontaneously coherent 
cell-aggregates with other cells (heterotypic aggregation), heterotypic co-cultures 
can be reproducibly established (Kim JB, 2005). These individually designed 
heterotypic co-cultures can comprise virtually all stromal cell types which allow 
evaluating the drug’s pharmacological properties more reliable. Since cellular 
interactions and activation (e.g. gene expression, cellular crosstalk, cell behavior and 
proliferation) is controlled by the local surrounding the microenvironment is 
determining the cell’s fate. Nevertheless it is not only the neighborhood of cells which 
is crucial but also the defined composition of extracellular macromolecules (e.g. 
fibronectin, collagen and laminin) and mediators (e.g. hormones, cytokines and 
growth factors) present. Only fine-tuned physico-chemical and biological parameters 
ensure optimal micro-environmental conditions that mimic the in vivo situation as 
closely as possible (Figure 7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Environmental factors that affect cell behavior and consequently the evaluation of drug efficacy.  
Many aspects must be taken into consideration when generating organotypic microenvironments. The cells or cell 
aggregates (spheroids, center) are heavily dependent on various parameters which must be fine tuned in order to ensure an 
accurate reflection of cell behavior in vivo.  
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Every tissue in vivo possesses certain characteristics which are defined by their 
molecular compositions. Dependent on the cancer type each 3D tumor model 
therefore must comprise appropriate molecular and macroscopic architecture in 
order to mimic the phenotype of different tissues appropriately in vitro. Natural 
biomaterials including purified ECM proteins such as collagen or fibronectin and 
ECM derivatives such as Matrigel™ or SIS™ are commonly used in tissue 
engineering. Due to their natural origin these biomaterials can mimic function and 
structure of the native extracellular environment very closely. Beside natural 
biomaterials also a broad range of synthetic polymers are being used as scaffolds for 
3D models, i.e. poly (α-hydroxy acids) of aliphatic polyesters such as PLA, PGA and 
PLGA (Marx U and Sandig V, 2007). The ability to control rigidity, processability, 
inertness, microstructure and permeability very precisely is one of the main 
advantages of synthetic materials (Vacanti JP and Langer R, 1999).  
In addition, the different cell types in this heterotypic tumor-model can be stably and 
differently labeled with fluorescent proteins using e.g. retroviral vectors. This allows 
for tracking the fates of the different cell types and studying the effect of cellular 
crosstalk on drug efficacy.  
The combination of individual tumor cell-aggregates, various biological or synthetic 
ECM scaffolds and stromal cells of any lineage makes this approach so versatile and 
powerful for future anti-cancer drug discovery.  
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 Objectives of this Master Thesis  2.5
 
Today’s classical approach to evaluate new anti-cancer drugs is to screen large 
libraries of chemically synthesized compounds on two-dimensionally cultured cancer 
cell lines. Since life is three-dimensional it will apparently lead to the conclusion that 
three-dimensional cues might be essential in the regulation of cell physiology. Two-
dimensionally grown cells are not in their ecological niche by which they are 
regulated by a multitude of stimuli. It is well known that 3D cultures can maintain 
biochemical and morphological features similar to those found in their corresponding 
tissues in vivo – a fact, that makes them superior over conventional monolayer or 
suspension cultures. Nevertheless, it still remains elusive if 3D models could fill the 
gap between conventionally cultured cancer cell lines and clinical studies in the drug 
developmental process.  
 
Since lung cancer accounts for more deaths than any other cancer type we focus on 
the most frequent (80%) lung cancer subtype, Non-small cell lung cancer. The aim of 
this thesis is to develop an organotypic three-dimensional lung cancer model as an 
HTS-amenable test system that mimics the human tissue microenvironment as 
accurate as possible. For this purpose, different methods to generate multicellular 
spheroids need to be evaluated for their applicability or must be newly developed.  
 
Different methods to generate spheroids:  
• Hanging Drop  
• Rotary Cell Culture System (RCCS)  
• Methylcellulose; formation of spheroids in semisolid media  
• Coated surfaces that inhibit cell attachment (poly-HEMA, HydroCell™)  
 
Each tissue has its unique composition and therefore individual physico-chemical 
properties. To mimic the ideal microenvironment for lung cancer cells we evaluate 
different matrices for their applicability in that model.  
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Natural vs. synthetic ECM-surrogates: 
• Natural Source:  
o Matrigel™  
o Rat tail collagen type I  
• Synthetic Material:  
o HyStem; Hyaluronan-based hydrogel  
o HydroMatrix™ peptide nanofibers scaffold  
 
To compare expression and localization of marker proteins in 2D and 3D, protocols 
for immunofluorescent staining of embedded spheroids need to be developed.  
 
In order to determine the impact of cellular crosstalk on the invasive potential of 
tumor cells heterotypic co-cultures of tumor and stromal cells must be established.  
One possibility to discriminate between different cell types in co-cultures is by 
transduction of the cells to stably express fluorescent proteins. For this the lentiviral 
transduction system LentiORF™ (Thermo Fisher Scientific), will be used to 
transduce human fibroblasts and lung cancer cells.  
 
Microarray analyses and Phospho-Proteome Antibody Arrays will be used to 
determine differential gene expression and altered phosphorylation patterns of 
cancer-related proteins.  
 
The therapeutic efficacy of a candidate anti-cancer agent can be evaluated by 
means of its ability to induce the reversion of the acquired cancer hallmark 
capabilities. We chose two conventional chemotherapeutics (paclitaxel, Cis-
Diamminedichloroplatinum) and a SMWC targeting the EGFR (Gefitinib). It has been 
consistently reported that a majority of lung cancer patients carry EGFR mutations 
which strongly influence the progress of disease.  
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 Material and Methods 3
 
All described procedures in this section were conducted aseptically unless otherwise 
stated.  
 
 Cell Culture 3.1
Primary neonate human dermal fibroblasts (nHDF), obtained from Innoprot (Derio, 
Spain), were cultivated in fibroblast growth medium (Promocell; C-23010). The lung 
adenocarcinoma cell lines HCC827, NCI-H1437 and NCI-H1975 were obtained from 
the American Type Culture Collection (ATCC; Rockville, Maryland) and cultivated in 
RPMI-1640 (Gibco, Life technologies) growth medium supplemented with L-
Glutamine, Penicillin/Streptomycin and fetal bovine serum (HCC827, 15%; NCI-
H1437 and NCI-H1975 10%). The lung epidermoid carcinoma cell line CaLu-1 was 
obtained from the American Type Culture Collection (ATCC; Rockville, Maryland) 
and cultivated in McCoy’s 5A-GlutaMAX growth medium (Gibco, Life technologies) 
supplemented with L-Glutamine, Penicillin/Streptomycin and 10% fetal bovine 
serum. All cell lines were propagated using 0.25% Trypsin-EDTA. Trypsin was 
inactivated by the addition of fresh growth medium and cells were harvested by 
centrifugation at 240 x g for 3 min. Neonate HDF cells were centrifuged for 5 min at 
240 x g. Cells were grown in T25, T80 and T175 cell culture flasks and 100 mm petri 
dishes w/Nunclon™ Δ surface (Thermo Fisher Scientific, Huntsville, AL, USA).  
 
 Spheroid Generation 3.2
In order to produce spherical cell aggregates termed spheroids, conditions in which 
the adhesive forces between the cells are greater than for the substrate it is plated 
on are required (Kim JB, 2005). For this various methods were used.  
 
Material and Methods 
 
 
Nico Jacobi  45/111 
 Hanging Drop Method  3.2.1
The cells were suspended in 20 µL droplets of medium where they spontaneously 
develop into coherent spherical cell aggregates within 1-2 days of incubation at 37°C 
and 5% CO2 in a humidified atmosphere.  
 
Starting from a cell monolayer the cells were harvested as described above (see Cell 
Culture), counted and the concentration was adjusted to 2500 cells/ mL. 20 µL of this 
cell suspension was dispensed onto the inward of an inverted 100 mm culture dish 
lid. The lid was inverted and placed on the dish bottom containing 10 mL of 1x 
Phosphate buffered saline, PBS, (Life Technologies, Cat#10010-023) to avoid 
evaporation of droplets during incubation (Figure 8). After 48h of incubation at 37°C 
and 5% CO2 in a humidified atmosphere the spheroids were harvested by inverting 
the lid and aspirating the droplets to collect the suspension in a conical tube. Since 
the spheroids within a certain cell type are of similar shape and diameter (e.g. 
HCC827 ~550 µm; NCI-H1975 ~800 µm) the sedimentation time was determined 
and the clear supernatant could be aspirated after 5 min in order to adjust the 
spheroid concentration for further experiments.  
 
 
 
 
 
 
 
 
 
 
 Spheroid Generation via Rotary Cell Culture Systems™  3.2.2
By simulating microgravity the by NASA developed rotary cell culture system 
(RCCS) maintains cells in a suspension with low hydrodynamic forces which allows 
the cells to aggregate and to form for spheroids (Figure 9). Due to a semi-permeable 
Figure 8: Formation of multicellular tumor spheroids by hanging drop method.  
A| 20 µL droplets of cancer cell suspension (2500 cells per mL) are dispensed onto 100 mm culture dish lid. B| The lid is 
inverted and placed on the culture dish tray with a reservoir of 1x PBS to avoid evaporation of medium during incubation. 
C| Within 24-48h the cells sink to the bottom of the droplet and form cell-cell contacts. D| The resulting multicellular 
spheroid (one per droplet) is supplied with sufficient nutrients and growth factors by the growth medium while residing on 
the bottom of the droplet. After formation the spheroid is harvested for further experiments.  
A B C D 
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membrane each vessel provides sufficient aeration and inhibits bubble formation 
which otherwise would result in high shear forces (Kim JB, 2005).  
After equilibrating the 10 mL rotary wall bioreactor vessel (RCCS-4DQ, Synthecon 
Inc., Houston, Texas) with 1xPBS for at least 30 min, the cells were harvested and 
counted as described above (see Cell Culture), 1 x 106 cells were seeded into each 
vessel and incubated at 37°C and 5% CO2 in a humidified atmosphere. For each 
specific cell line optimal incubation time and rotation speed were determined (e.g. 
HCC827 48-72h at 6.3 rpm; NCI-H1975 48h 7.0 rpm). To ensure optimal spheroid 
formation the individual growth medium was replaced after 48h. After cell line 
dependent duration of incubation the spheroids were harvested, counted and the 
desired concentration for further experiments was adjusted after centrifuging the 
spheroid suspension for 10 s at 235 x g and aspirating the respective excess volume 
of supernatant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Spheroid generation on coated surfaces to inhibit cell attachment 3.2.3
To induce spontaneous spheroid formation, conditions in which the adhesive forces 
between the cells must be greater than for the substrate it is plated on. For this 
purpose cells are grown either in semisolid medium (Methylcellulose), on semisolid 
Figure 9: Rotary Cell Culture System (RCCS)  
The NASA developed RCCS allows for the generation of 3D cell aggregates due to low shear 
force, high mass transfer and microgravity. The 4x2 station rotation base allows the installation of 
8 RCCS bioreactor vessels. Via 4 tachometers on the power supply unit the individual rotation 
speed can be adjusted for pairs of two vessels respectively. 
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substrate (Agarose) or on substrates coated with plastic which prevent cell 
attachment (poly-HEMA, NUNC Hydrocell plates).  
 
Methylcellulose solution| In order to prepare the highly viscous methylcellulose 
solution 1.2 g of the pure powder (Sigma Aldrich, Cat#M0512, 4000 Centipoises) 
were autoclaved. Subsequently the powder was dissolved in 50 mL pre-warmed 
basal medium (60°C) for 20 min under continuous stirring. After the addition of 50 
mL basal medium (RT) the solution was mixed by rotation overnight (o/n) at 4°C. 
This solution was centrifuged at 5,000 x g for 2h at RT. The highly viscous clear 
supernatant, comprising 90-95% of the total volume, was finally used for spheroid 
generation upon 5-fold dilution with the cell suspension of desired concentration. For 
this purpose 200 µL of the cell suspension comprising 40 µL of methylcellulose 
solution was dispensed per well of a round bottom 96-well suspension culture plate 
(Greiner, Cat#650185) and subsequently centrifuged at 850 x g for 2 min. Cells were 
incubated at 37°C and 5% CO2 in a humidified atmosphere to develop 
spontaneously into spheroids within 2 days.  
 
Agarose coating| For coating of various surfaces to inhibit cell attachment and to 
promote spontaneous spheroid formation 1% agarose solution dissolved in growth 
medium was used. For this purpose 1 g of agarose was dissolved in 100 mL sterile 
basal medium by repeated heating using a microwave oven. Immediately after 
complete dissolution 500-750 µg agarose were added per cm2 surface area. 
Subsequently, the hot agarose solution was aspirated and incubated at 37°C for 30 
min. The cell suspension intended to form spheroids was added to the residual 
agarose film and incubated for 24-48 hours at 37°C and 5% CO2 in a humidified 
atmosphere.  
 
Poly-HEMA coating| To prepare a 1.2% poly 2-hydroxyethyl methacrylate (poly-
HEMA) solution for generating surfaces which prevent cell attachment 2.4 g poly-
HEMA (Sigma Aldrich, Cat#P3932) was dissolved in 20 mL 95% ethanol for 8h at 
65°C under continuous stirring. Subsequently, this solution was 10-fold diluted with 
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95% ethanol to a final poly-HEMA concentration of 1.2%. Surfaces were coated 
using 0.8 – 1 mg/cm2 final coating concentration. The solution was dried at 37°C o/n 
in the oven. After evaporation, the cell suspension was added in the desired 
concentration (Table 1) onto the poly-HEMA coated surface and incubated for 24-
48h at 37°C and 5% CO2 in a humidified atmosphere to form spheroids.  
 
 
 
 
 
 
 
 
 
 
 Embedding of Spheroids  3.3
Spheroids were embedded in matrices consisting of Matrigel™ (Basement 
Membrane Matrix, BD Biosciences, Cat#354234) collagen type 1 (Rat Tail Collagen, 
BD Biosciences, Cat#354236) or mixtures of these.  
 
Matrigel was removed from frozen storage (-20°C) and placed on ice to thaw o/n at 
4°C until ready for use. BD Biosciences’ formulation of rat tail collagen type 1 in 
0.02N Acetic Acid started to gel when its pH was brought to alkalinity. Upon addition 
of 1N NaOH (2.3% of the final volume of collagen to be used) and 10xPBS (10% of 
the final total volume; pH 7.4, Life Technologies, Cat#70011-069) the collagen 
formulation was close to physiological pH and started to gel as indicated through 
advancing turbidity. The spheroid suspension (see Spheroid Generation) was used 
to dilute the matrix (Matrigel, collagen type 1) to the desired final concentration. The 
spheroid-matrix suspension was dispensed into the appropriate labware (see Table 
2). Complete gelation of matrix was achieved by incubating at 37°C for 
approximately 60-180 min dependent on matrix volume and labware. After entire 
Cell	  Line
Number	  of	  Cells/well	  
[104]
Incubation	  Period	  
[hours]
CaLu-­‐1 1.5 18
HCC827 1.5 48
NCI-­‐H1437 2 36
NCI-­‐H1975 1 24
Generation	  of	  Spheroids	  in	  poly-­‐HEMA	  coated	  flat	  
bottom	  96-­‐well	  plate	  
Table 1: The table indicates the optimal cell number for the 
generation of spheroids of each of the tested lung cancer cell lines 
in poly-HEMA coated flat bottom 96-well microtiter plates.  
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gelation the matrix was overlaid with appropriate medium for subsequent incubation 
at 37°C and 5% CO2 in a humidified atmosphere.  
 
 
 
 
 
 
 
 
 
 
 Immunostaining  3.4
Immunostaining of lung cancer cell lines for the characterization of marker protein 
expression was performed in 8-well Lab-Tek™ labware (Thermo Scientific, 
Cat#177445) with the Permanox® resin slide. Immunostaining was performed under 
non-sterile conditions. 
 
 Two-dimensional monolayer  3.4.1
48h after cell seeding the wells were washed with prewarmed (37°C) Hanks’ 
Balanced Salt solution (HBSS, Life technologies, Cat#14025). After 30 min of fixation 
with 2.5% formalin (Carl Roth, Cat#4980.1) in HBSS the cells were washed with 
HBSS following PBS. Cells were permeabilized with 0.2% Triton® X-100 (Sigma 
Aldrich, Cat#T8787) in PBS for 15 min, washed with PBS and subsequently treated 
for 20 min with 50 mM NH4Cl/0.1% Glycine in PBS (quenching of background prior 
to antibody incubation). Incubation of 1st antibody (Table 3) was performed o/n at RT 
with consequent 1xPBS washing. Incubation of 2nd antibody (Table 3) was 
performed for 1 hr at RT following wash with 1xPBS and deionized water. 
Additionally fluorescent-phalloidin (Alexa-Fluor® 568-phalloidin, Life Technologies, 
Cat#A12380) was diluted 1:800 in 2nd antibody solution to stain actin filaments. After 
removal of chambers and gaskets, VECTASHIELD® mounting medium containing 
Labware Surface	  Area	  [cm2] Matrix	  Volume	  [µL]
96-­‐w	  fl	  btm 0.33 60-­‐100
48-­‐w 0.95 90-­‐200
24-­‐w 1.91 150-­‐400
8-­‐w	  Lab-­‐Tek™ 0.8 100-­‐150
Matrix	  Volumina	  in	  different	  Labware
Table 2: The table indicates the working ranges of matrix volumes 
used in the different lab wares. In addition the specific surface areas 
of each used lab ware are listed. w, well; fl btm, flat bottom. 
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DAPI (Vector Laboratories, Cat#H-1500) was added to the coverslips and dried o/n 
at RT protected from light.  
 
 Three-dimensional organoids  3.4.2
Spheroids were embedded in matrices consisting of Matrigel™ (Basement 
Membrane Matrix, BD Biosciences, Cat#354234) and collagen type 1 (Rat Tail 
Collagen, BD Biosciences, Cat#354236). Immunostaining of embedded microtumors 
for the characterization of marker protein expression was performed as described 
above for two-dimensional Immunostaining with a few adaptations. After the 
spheroid generation the cell aggregates were embedded in ECM (50 µL Matrigel™, 
50 µL Collagen I, 50 µL growth medium). Samples were incubated with regular 
medium exchange for 5-8 days at 37°C and 5% CO2 in a humidified atmosphere 
prior to immunostaining. Organoids were fixed for 1 hr using 3% formalin solution. 
Permeabilization and quenching was prolonged to 25 min. Secondary antibody 
incubation was prolonged to 3-4h.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antibody Antigen	  (Epitope) Dilution	  (in	  1xPBS) Supplier	  /	  Product	  No
Mouse	  mAb β-­‐catenin 1:100 BD	  Biosciences/#610154
Mouse	  mAb E-­‐cadherin 1:100 BD	  Biosciences/#610182
Mouse	  mAb Integrin	  beta	  1 1:100 Abcam/#ab3167
Mouse	  mAb Ki67 1:100 Dako/#M7240
Goat	  pAb N-­‐cadherin 1:100 Santa	  Cruz/#SC-­‐1502
Mouse	  mAb pan	  Cytokeratin 1:100 Abcam/#ab17155-­‐1
Mouse	  mAb Vimentin 1:100 Dako/#M0725
Rabbit	  pAb ZO-­‐1 1:100 Abcam/#ab59720-­‐50
F(ab´)2-­‐Conjugate/Host Antigen	  (Epitope) Dilution	  (in	  1xPBS) Supplier	  /	  Product	  No
Alexa	  Fluor	  488/Goat anti-­‐mouse 1:400 Life	  Technologies/#A11017
Alexa	  Fluor	  488/Goat anti-­‐rabbit 1:400 Life	  Technologies/#A11070
Table	  A	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Primary	  Antibodies	  used	  in	  Immunostaining
Table	  B	  	  	  	  	  	  	  	  	  	  Secondary	  Antibody	  Fragment	  Conjugates	  used	  in	  Immunostaining
Table 3: The tables list the primary antibodies (A) and secondary antibody fragments (B) used in 
immunostaining experiments. Mouse, Rabbit, Goat: the species of the host animal in which the antibody was 
raised; mAb: monoclonal antibody; pAb: polyclonal antibody. 
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 RNA Preparation 3.5
Even though gene expression studies have focused mainly on mRNA levels smaller 
RNA species like miRNA take center stage in the last years. In order to purify total 
RNA including miRNA from 2D and 3D cultures Qiagen’s miRNeasy Mini Kit 
(Qiagen, Cat#217004) was used.  
 
 Two-dimensional cell monolayer  3.5.1
48-72h before RNA preparation 1.5 x 106 cells were seeded per 100 mm culture dish 
(Nunc™, Cat#150350). To prepare total RNA from cell monolayer the cells were 
washed on the day of RNA preparation with 1xPBS before QIAzol® lysis reagent was 
added. After 5 min of incubation at RT the cell lysate was transferred into centrifuge 
tubes and chloroform was added (1/5 of the total QIAzol® volume added). The tubes 
were placed at RT for 3 min for subsequent centrifugation at 12,000 x g for 15 min at 
4°C. The resulting upper aqueous phase (70-80% of total volume) was transferred 
and 1.5 volumes of 100% ethanol were added and mixed. After several 
centrifugation steps (according to manufacturer’s instructions) using the RNeasy Mini 
columns, 1.5 µL of the samples containing the purified RNAs was used for RNA 
quality determination (see Experion™ RNA Quality Determination); the remaining 
samples were stored below -80°C for RNA expression profiling using affymetrix gene 
chip technology.  
 
 Three-dimensional organoids  3.5.2
72-96h after seeding single cells into the rotary cell culture bioreactor (RCCS-4DQ, 
Synthecon Inc., Houston, Texas) spheroids were harvested, embedded in 
Matrigel/collagen type I matrices diluted with growth medium (equal amounts) and 
incubated in 48-well plates (Greiner, Cat#677102) at 37°C and 5% CO2 in a 
humidified atmosphere. 6 days after embedding, matrices were washed with 1xPBS 
before QIAzol® lysis reagent was added and protocol conducted as described 
previously in RNA Preparation of two-dimensional cell monolayer (see previously).  
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 Experion RNA Quality Determination  3.5.3
Preliminary RNA quality tests before RNA expression profiling were performed using 
the capillary gel electrophoresis platform Experion™ and Experion RNA StdSens 
Analysis Kit (Cat#700-7104) by Bio-Rad. For quality determination the 1.5 µL of RNA 
samples prepared using the miRNeasy Mini Kit (Qiagen) and RNA ladder were 
heated up for 2 min at 70°C to be immediately cooled down on ice for 5 min. After 
priming the analysis chips with gel-stain solution using the Experion Priming Station 
(Cat#700-730) 7.5 µL loading buffer was added to the pre-heated sample, mixed and 
6 µL of final mixture was loaded into each well of primed Bio-Rad’s StdSens Analysis 
Chips. After loading 9 µL gel-stain solution and 9 µL unstained gel into the indicated 
wells the RNA quality was measured on the Experion™ gel electrophoresis platform 
(Software Version 3.1).  
 
 Determining drug efficacy in lung cancer cell lines by alamar-3.6
Blue assay  
AlamarBlue® Cell Viability Reagent (Life Technologies, Cat#DAL110) was used for 
rapid and quantitative determination of cell proliferation and viability.  
 
 Sensitivity Testing  3.6.1
Cells grown in Monolayer| Serial dilution of lung cancer cell lines CaLu-1, HCC827, 
NCI-H1437 and NCI-H1975 (ATCC; Rockville, Maryland) ranging from 1 x 105 – 195 
cells per well was performed to evaluate the sensitivity of alamarBlue® reagent. 200 
µL cell suspension was dispensed per well of a black, clear-bottom 96-well plate 
(Nunc™, Cat#165305) and incubated for 24h at 37°C and 5% CO2 in a humidified 
atmosphere. 20 µL of alamarBlue® reagent was added to each well and incubated 
for 6h at 37°C and 5% CO2 in a humidified atmosphere. Data were assessed using 
the PARADIGM™ Detection Platform (Beckman Coulter/Molecular Devices, 
Multimode Analysis Software Version 3.3.0.9) and appropriate fluorescence intensity 
detection cartridge (Beckman Coulter/Molecular Devices, Cat#A56150) at 595 nm.  
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Spheroids| Additionally serial dilutions of spheroids generated from the same lung 
cancer cell lines as described above were performed to evaluate the sensitivity of 
alamarBlue® reagent with spherical cell aggregates. Spheroids were generated using 
poly-HEMA coated 96-well plates (see poly-HEMA coating) and serially diluted 
ranging from 160 – 5 spheroids in per well of a black, clear-bottom 96-well plate 
(Nunc™, Cat#165305). After 4 hours of incubation at 37°C and 5% CO2 in a 
humidified atmosphere alamarBlue® reagent was added and assay performed as 
described in the sensitivity testing of cells grown in monolayer above.  
 
 Viability Assay after Therapeutic or Targeted Therapies  3.6.2
Treatment of cells grown in monolayer| Lung cancer cells were seeded (CaLu-1, 
1.5 x 104; HCC827, 1.5 x 104; NCI-H1437, 2 x 104; NCI-H1975, 1 x 104; cells per 
well) into transparent flat bottom 96-well plates (Nunc™, Cat#125174) and incubated 
for 24h at 37°C and 5% CO2 in a humidified atmosphere. Cells were treated with Cis-
Diamminedichloroplatinum (Sigma Aldrich, Cat#P4394), paclitaxel (LC Laboratories, 
Cat#P-9600) or Gefitinib (LC Laboratories, Cat#G-4408) and incubated for 96h at 
37°C and 5% CO2 in a humidified atmosphere. Data were assessed (Figures 28, 30) 
using the PARADIGM™ Detection Platform (Beckman Coulter/Molecular Devices) 
and appropriate fluorescence intensity detection cartridge (Beckman 
Coulter/Molecular Devices, Cat#A56150) at 595 nm.  
 
Treatment of spheroids| Spheroids were generated using poly-HEMA coated 96-
well plates (see poly-HEMA coating) and treated with the four therapeutics depicted 
for the treatment of cells grown in monolayer mentioned in the previous point.  
 
Treatment of organoids| Spheroids were generated using poly-HEMA coated 96-
well plates (see poly-HEMA coating), embedded in Matrigel/Collagen Type 1 
matrices (see Embedding of Spheroids) and incubated at 37°C and 5% CO2 in a 
humidified atmosphere. Medium was exchanged after 48h. 4 days after embedding 
organoids were treated the four therapeutics depicted for the treatment of cells 
grown in monolayer mentioned above.  
Material and Methods 
 
 
Nico Jacobi  54/111 
 
 
 
 Phospho-Profiling  3.7
In order to detect changes in phosphorylation between samples of tumor cells 
cultured as a monolayer or as three-dimensional organoids various Proteome 
Profiler™ Antibody Arrays (R&D Systems, ARY001, ARY002B, ARY003 and 
ARY009) were used. As a representing array the protocol of the human phospho-
RTK Array Kit (R&D Systems, Cat#ARY001) is exemplified.  
 
 Sample Preparation  3.7.1
48-72h before Phospho-profiling cells were plated at different cell line specific 
concentrations (1.5 - 4 x 106) onto 100 mm culture dishes (Nunc™, Cat#150350). 
For three-dimensional organoids, spheroids were generated using poly-HEMA 
coated 96-well plates (see poly-HEMA coating), embedded in Matrigel/Collagen 
Type 1 matrices (see Embedding of Spheroids) and incubated at 37°C and 5% CO2 
in a humidified atmosphere in 48-well plates (Greiner, Cat#677102). Medium was 
exchanged after 48h. 6 days after embedding organoids were lysed. To prepare cell 
lysates from cell monolayer and organoids the cells were washed with 1xPBS (Life 
Technologies, Cat#10010-023) before NP-40 lysis buffer (Table 4) was added. For 
the adequate inhibition of proteases protease inhibitor tablets complete, ULTRA, Mini 
(Roche, Cat#05892970001) were added supplementary to the lysis buffer. Cells 
were incubated with lysis buffer for 60 min at 2-8°C on a rocking table. During cell 
lysis the nitrocellulose membranes were blocked. A small aliquot of the lysates was 
diluted at a 1:1 ratio with standard Laemmli Buffer containing Dithiothreitol, SDS and 
Tris-Cl and frozen at -20°C for prospective SDS-PAGE experiments. The lysates 
were added to the membranes and incubated o/n at 2-8°C on a rocking table. The 
membranes were washed and the detection antibody (Anti-Phospho-Tyrosine-HRP 
antibody) was added to each membrane for 2h at RT on a rocking table. Afterwards 
the membranes were washed, and chemiluminescent western blotting substrate 
(Pierce, Cat#32106) was added to the membranes. The signal was detected by the 
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ChemiDoc XRS platform (Bio-Rad, Cat#170-8070) using the high sensitivity mode 
and analyzed with Quantity One Software.  
 
 
 
 
 
 
 
 
 
 
 
 
 Western Blot  3.8
For the determination of protein amount in the cell lysate samples (see Phospho-
Profiling) western blotting was performed. RPLP0, a ribosomal protein and actin, a 
cytoskeletal protein serve as appropriate candidates to compare lysate samples of 
cells cultured as a monolayer or as three-dimensional organoids.  
 
 Sample Preparation and SDS-PAGE 3.8.1
Lysate samples (see Phospho-Profiling) were removed from frozen storage (-20°C) 
and placed on ice. After heating up the thawed samples to 95°C for 5 min they were 
brought to RT to perform the SDS-PAGE. The electrophoresis was performed in 
vertical electrophoresis chambers (Mini-PROTEAN® Tetra Cell, Cat#165-8001). 25 
µL of samples were loaded into each well of the polyacrylamide gel (10% TGX Mini-
PROTEAN®, Bio-Rad, Cat#456-1033) and run at constant 60 mA for 40 – 45 min 
(TGS Running buffer, Bio-Rad, Cat#151-0772).  
 
Components Proportion/Concentration Product	  Informartion
NP-­‐40 1% Igepal,	  Sigma	  Aldrich;	  #CA-­‐630
Tris-­‐HCl 20	  mM,	  pH	  8.0 Life	  Technologies;	  #15568-­‐025
EDTA 2	  mM Life	  Technologies;	  #15575-­‐020
NaCl 137	  mM Merck;	  #1.06404.1000
Glycerol 10% Merck;	  #1.04091.9025
Na3VO4 1	  mM Sigma	  Aldrich;	  #S6508
NP-­‐40	  Lysis	  Buffer
Table 4: The table lists the individual components and their concentrations of the NP-40 lysis 
buffer used in the Receptor-Tyrosine Kinase Proteome Profiler™ Antibody Array 
(Cat#ARY001, R&D Systems). NP-40: (Octylphenoxy)- polyethoxyethanol, IGEPAL® CA-630; 
EDTA: Ethylenediaminetetraacetic acid; NaCl: sodium chloride; Na3VO4: sodium 
orthovanadate.  
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 Western Blot 3.8.2
After SDS-PAGE the gel was sandwiched between ion reservoir stacks along with a 
0.2 µm nitrocellulose membrane (Trans-Blot Turbo Transfer Pack, Bio-Rad, 
Cat#170-4158). The assembly was placed between the anode of the cassette base 
of the Trans-Blot® Turbo Blotting System (Bio-Rad, Cat#170-415) and the cathode in 
the cassette lid. The proteins were transferred by applying 1.3A, 25V for 7 min using 
the Trans-Blot® System. After the transfer the blotting sandwich was disassembled 
and the gel was stained with Bio-Safe Coomassie Stain (Bio-Rad, Cat#161-0787) for 
60 min on a rocking table.  
 
The nitrocellulose membrane was washed with PBST, 1xPBS, (Life Technologies, 
Cat#10010-023) containing 0.05% Tween® 20 (Merck, Cat#8.22184.0500) and 
subsequently blocked with PBST containing 2% BSA for 30 min at RT on a rocking 
table. After a wash with PBST the primary antibody (Anti-RPLP0, 1:2000, Sigma 
Aldrich, Cat#AV40221; Anti-Actin, 1:200, Sigma Aldrich, Cat#A2066) was diluted in 
PBST containing 2% BSA, applied to the membrane and incubated for 1h at RT on a 
rocking table. After that the membrane was washed entirely with PBST and the 
secondary antibody (Anti-Rabbit IgG-HRP conjugate, 1:2000, DakoCytomation, 
Cat#P0448) was diluted in PBST containing 2% BSA, applied to the membrane and 
incubated for 1h at RT on a rocking table. After the secondary antibody incubation 
the membrane was washed with PBST and deionized water for subsequent data 
acquisition.  
 
 Chemiluminescence Detection  3.8.3
Chemiluminescent western blotting substrate (GE Healthcare, Cat#RPN2132) was 
prepared and added to the membranes. The signal was detected by the ChemiDoc 
XRS platform (Bio-Rad, Cart#170-8070) using the high sensitivity mode and 
analyzed with Quantity One Software.  
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 Microscopy 3.9
Cell behavior and phenotypic changes of tumor and stromal cells were evaluated by 
confocal laser scanning microscopy and phase-contrast microscopy methods.  
 
 
 Confocal microscopy  3.9.1
Confocal laser scanning microscopy was performed using a Leica DMIRE2 
microscope equipped with a TCS SP2 laser unit, EL6000 compact light source, CTR 
MIC electronics box and Leica Confocal Software Version 2.61 (Leica Microsystems, 
Heerbrugg, CH). The microscope was interfaced with argon, argon/krypton and 
helium/neon laser. Additionally, the microscope unit was equipped with an EL6000 
compact light unit. This set-up covered an emission spectrum from 405 to 633 nm 
and was therefore suitable for the excitation of the fluorescent proteins mCFP (433 
nm), EGFP (488 nm) and J-Red (584 nm) which were used for labeling the target 
cells. The fluorescent proteins’ emission was detected by four photomultiplier tubes.  
 
 Phase-contrast microscopy  3.9.2
Phase-contrast microscopy was performed using a Leica DMI6000B inverted 
microscope equipped with CTR6500 microscope drive control, DFC420C digital 
microscope camera with a 5 Megapixel CCD sensor and Leica Application Suite 
Version 3.8.0 software.  
 
 Lentiviral Transduction  3.10
The lentiviral system LentiORF™ was purchased from Thermo Fisher Scientific, 
(formerly Open Biosystems) and consisted of five trans-lentiviral packaging 
plasmids, pTLA1-Pak, pTLA1-ENZ, pTLA1-ENV, pTLA1-Tat/Rev and pTLA1-TOFF 
(Figure 10) that supplied all viral proteins in trans and were required for the 
production of replication incompetent lentiviral particles. Furthermore the LentiORF™ 
system contained a transfection reagent (Express-In™), TLA-HEK293T packaging 
cell line, control vectors and ORF plasmid DNA. The fluorescent proteins, J-Red, 
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mCFP and EGFP were cloned into the multiple cloning site (MCS) of the pLEX 
empty vector. The EGFP expressing vectors were packaged into viral particles and 
stably transduced into the lung cancer cell lines HCC827, NCI-H1975 whereas 
primary human neonate dermal fibroblasts (nHDF) where lentivirally transduced to 
express J-Red or mCFP respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The packaging cell line TLA-HEK293T was plated at a density of 5.5 x 106 cells per 
100 mm culture dish in DMEM medium (Life technologies, Cat#11960-044). After o/n 
incubation at 37°C and 5% CO2 in a humidified atmosphere the lipo-polymeric 
transfection reagent Express-In™ (Life Technologies, Cat#ETR4620) facilitated high 
Figure 10: The packaging plasmids of pLEX System supply helper functions as well as structural and 
enzymatic proteins in trans to produce replication incompetent lentiviral particles.  
pTLA1-Pak contains the gag-pro gene controlled unter a strong TRE-CMV promoter. Gag-pro encodes structural 
proteins (gag-pro) essential for assembly and packaging the new virus within the packaging cell line. pTLA1-ENZ 
contains the accesory gene vpr, as well as the viral enzymes reverse transcriptase (RT) and integrase (IN). Genes 
encoding viral surface and transmembrane glycoproteins which are essential for the recognition and infection of the 
target cells are located on plasmid pTLA1-ENV. pTLA1-TOFF is required for the transcriptional activation of Gag-pro 
(pTLA1-Pak) and Tat/Rev (pTLA1-Tat/Rev) expression. pTLA1-Tat/Rev contains the viral genes tat and rev and 
includes an internal ribosomal entry site (IRES). Tat expression is required for transactivation of 5’LTRs whereas rev 
is necessary for the nuclear transport and the translation of mRNA transcripts and the full-length viral genome. 
(Image source: Thermo Scientific Open Biosystems) 
Material and Methods 
 
 
Nico Jacobi  59/111 
yield transfection of lentiviral vectors into packaging cells. The resulting lentiviral 
particles containing supernatant was diluted to 12.5% with appropriate growth 
medium to transduce target cells. Non-infected cells were eliminated using 
puromycin containing growth medium (1 µg/mL) for 2 weeks.  
 
 
 Fluorescent Proteins 3.10.1
Enhanced green fluorescent protein (EGFP), a modified Aequorea-derived 
fluorescent protein (AFP), is widely-used and emits green fluorescence at 509 nm 
when excited at 488 nm. The enhancement was accomplished by modifying GFP at 
two positions, i.e. F64L and S65T. It is a well characterized FP in terms of 
brightness, folding efficiency, photostability and cytotoxicity and represents therefore 
an optimal candidate. Monomeric cyan fluorescent protein (mCFP) emits blue 
fluorescent light at 475 nm when excited at 433 nm. Monomeric CFP comprises 
seven mutations relative to wtGFP, i.e. F64L, S65T, Y66W, N149I, M153T, V163A 
and A206K (Shaner NC et al., 2005). J-Red is a red fluorescent protein obtained by 
mutagenesis of a chromoprotein of an unidentified Anthomedusae jellyfish (Shagin 
DA et al., 2004) and emits red fluorescent light at 610 nm when excited at 584 nm.  
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 Results  4
 
According to American Cancer Society the lifetime risk of developing cancer is 42%. 
Approximately the half of patients diagnosed with cancer will die of it. Hence, a 
primary area of contemporary medical research is the discovery and development of 
new anti-cancer drugs. Many advances have been produced by standard two-
dimensional (2D) cell culture studies so far. Despite this progress recent data from 
3D tumor model approaches indicate their decisive role in the evaluation of anti-
cancer drugs (Bhadriraju K et al., 2002; Kim JB, 2005).  
 
With approximately one third of all cancer deaths lung cancer accounts for more 
deaths than any other cancer type regardless of gender (American Cancer Society, 
2011). Since non-small cell lung cancer (NSCLC) accounts for 85% of all lung 
cancers we focused on this major subclass. We developed different methods to 
generate cancer cell spheroids that are miniaturized 3D cell aggregates (tissue 
mimetics) that can form under specific experimental cell culture conditions. Each 
cancer cell line required a specific experimental set up to form coherent 3D 
spheroids. The typical work flow for the generation and subsequent analyses of 
homo- and heterotypic 3D cultures is depicted in Figure 11.  
 
After generating spheroids with different experimental techniques we embedded 
them in natural or synthetic extracellular matrix (ECM) scaffolds and tested defined 
compositions of these ECM components with regard to their influence on tumor cell 
physiology. We phenotypically characterized human carcinoma cell lines in terms of 
their epithelial marker protein expression and differential proliferation when cultured 
in 2D or 3D. We already established an experimental workflow for the automatized 
generation of spheroids and organoids that might be amenable to high-throughput 
drug screening (Figure 11).  
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Figure 11: Generation of Tumor Mimetics.  
The flow chart depicts a typical work flow for the generation of organoids, possible applications and analysis methods. 
Poly-HEMA, poly 2-Hydroxyethyl Methacrylate; ECM, Extracellular Matrix; HTS, High-throughput screening; FACS, 
Fluorescence activated cell sorting.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To characterize the cell physiology of organotypic 3D models in more detail we 
performed Affymetrix Gene Chips analyses. By utilizing microarray technology the 
transcriptome analyses revealed differences in transcriptome patterns of cells 
cultured in 2D or 3D. In addition Proteome Profiler™ Antibody Arrays were used to 
measure more than 40 different proteins simultaneously. These arrays allowed 
identifying differences on the protein level (i.e. phosphorylation patterns of cancer-
related proteins) of cells grown in 2D or 3D. Moreover, it was demonstrated that drug 
response was significantly affected when cells were cultured as cell aggregates. The 
three-dimensionality of cell clusters and the physico-chemical cues of the 
surrounding microenvironment crucially influenced cell signaling and cell behavior 
and thereby drug sensitivity. It has been consistently shown that NSCLC frequently 
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overexpresses members of the erbB family, and that many NSCLC cells are 
“addicted” to signaling via mutated erbB family members (Riley GJ et al., 2006). 
Therefore we chose the listed cell lines on the basis of their mutations of the 
epidermal growth factor receptor HER1 to establish and validate a standardized 3D 
lung cancer model system (Table 5). For evaluating the ability of the 3D model to 
predict drug efficacy we tested EGFRIs (targeted anti-cancer agents) and 
conventional cytostatic therapeutics.  
Beside matrix related effects it is known that cellular crosstalk between tumor and 
stromal cells is a crucial factor in cancer cell proliferation and invasion. By co-
cultivating lung cancer cells with fibroblasts the effect of stromal cells on the cancer 
cells was shown. To discriminate microscopically between cancer cells and stromal 
cells both cell types were lentivirally transduced to stably express different 
fluorescent proteins.  
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 Phenotypic Characterization of Lung Cancer Cell Lines  4.1
 
It has been consistently demonstrated that physiological cell signaling and related 
morphological and functional cellular changes rely crucially on the attachment of 
cells to surrounding three-dimensional mesh-like fibers rather than to two-
dimensional coated surfaces (Cukierman E et al., 2002).  
 
 The used cell lines 4.1.1
The human lung cancer cell lines used in the experiments are fully genotyped. 
Selected cell line information including grading, HER1 and other mutations, type of 
malignancy and biological source of origin are listed in Table 5.  
HCC827 cell line carries an E746-A750 deletion on exon 19 of the HER1 receptor. 
This hyperactivation mutation together with a 10-fold amplification of HER1 might 
lead to HER1 oncogene addiction in this cell line. This feature results in an increase 
in sensitivity towards HER1 inhibitors such as Gefitinib and Erlotinib.  
In general, dramatic response to HER1 inhibitors may be ascribable to several HER1 
mutations (Kosaka T et al., 2004). NCI-H1975 cell line carries a drug sensitive point 
mutation, L858R, on exon 21. It has been reported that this missense mutation 
increases the EGF induced activation of the HER1 two to three-fold compared to 
wild-type HER1 receptors; additionally this mutation caused an up to 12-fold 
prolonged activation of the mutant receptor. The localization of the L858R mutation 
near the receptor’s ATP cleft causes a higher sensitivity towards HER1 inhibitors 
(Lynch TJ et al., 2004). In addition, this cell line carries a T790M point mutation on 
exon 20 which is associated with acquired drug resistance to Erlotinib or Gefitinib. 
This mutation impairs binding of the inhibitors to the tyrosine kinase domain. In 
contrast, CaLu-1 and NCI-H1437 cell lines express wild-type HER1 receptors.  
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We phenotypically characterized these human lung cancer cell lines via phase-
contrast and confocal laser scanning microscopy (Figure 12). To determine epithelial 
cell polarity and associated differentiation status of the carcinoma cell lines the cells 
were fixed in 2.5% formaldehyde for 30 minutes and processed for 
immunofluorescence microscopy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Name ATCC Cat. No. Type Tumor Stage HER1 Mutations Other Mutations Source
HCC827 CRL-2868 Adenocarcinoma n.a. p.746_750del; 10x Ampl.
PIK3CA: p.N797fs; PIK3CB: p.H280fs; 
PIK3R1: p.P612fs; RB1: p.557_557del; 
TP53: p.P72R, p.V218del; Met: 2.2x
Primary, lung epithelial
NCI-H1975 CRL-5908 Adenocarcinoma n.a. p.T790M, p. L858R TP53: p.P72R, p.R273H; PIK3CA: p.G118D; Met: 2.7x Primary, lung epithelial
CaLu-1 HTB-54 Epidermoid Carcinoma Grade III wt KRAS: p.G12C Metastatic, pleura
NCI-H1437 CRL-5872 Adenocarcinoma Grade I wt CDKN2a (p14ARF): c.471_471del; c.522_522delTP53: p.R267P Metastatic, pleural effusion
Table 5: Background information of used human lung cancer cell lines.  
The table provides information on two HER1 mutant and two HER1 wild-type NSCLC cell lines, including 
reopository number, type of malignancy, grading, EGFR (HER1) and other selected mutations and the biological 
source. 
Figure 12: Morphology and expression of 
cell-polarity marker E-cadherin in human 
lung cancer cell lines grown as monolayers.  
Phase-contrast (left panel) and confocal laser 
scanning micrographs(right panel)  show 
morphology and the distribution of E-cadherin in 
formaldehyde fixed cells after 
immunofluorescent staining. All investigated cell 
lines show high E-cadherin expression except 
CaLu-1 which feature a highly unpolarized 
phenotype mesenchymal phenotype). HCC827, 
NCI-H1437 and NCI-H1975 exhibit typical 
epithelial characteristics in terms of morphology 
and E-cadherin expression. Bars, 75 µm.  
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We could demonstrate that all used lung cancer cell lines except CaLu-1 highly 
expressed E-cadherin. HCC827, NCI-H1437 and NCI-H1975 cells showed typical 
epithelial characteristics. Therefore CaLu-1 cells adopted a mesenchymal, 
dedifferentiated morphology that correlated with phase-contrast micrographs (Figure 
12). It has been demonstrated that during EMT the loss of E-cadherin expression is 
concomitant with de novo vimentin expression (Eger et al., 2005). We could show 
that CaLu-1 cells highly up-regulated the type III intermediate filament protein 
vimentin (Figure 13).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The different lung cancer cell lines needed individually defined conditions to form 
spheroids using various methods. While NCI-H1975 and NCI-H1437 spheroids 
feature generally high stability and a smooth rim single invading single HCC827 and 
CaLu-1 cells are visible at the spheroid edge. Even though all used cell lines 
originate from epithelium, in a monolayer culture NCI-H1975 and especially CaLu-1 
Figure 13: Expression of intermediate filament protein 
vimentin in human lung cancer cell lines grown as 
monolayers.  
Confocal laser scanning micrographs of horizontal optical sections 
show the distribution of vimentin in formaldehyde fixed cells after 
immunofluorescent staining. All investigated cell lines show basal 
vimentin expression except CaLu-1 which feature a highly up-
regulated vimentin expression. This leads beside other molecular 
mechanisms to the acquisition of a mesenchymal phenotype. 
HCC827, NCI-H1437 and NCI-H1975 feature typical epithelial 
characteristics. Bars, 75 µm.  
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cells feature a rather mesenchymal phenotype. HCC827 and NCI-H1437 cells exhibit 
typical epithelial polarization and a cobblestone appearance.  
 
The immunofluorescence microscopy revealed the differential expression of EMT 
associated markers in the carcinoma cell lines. In CaLu-1 cells the downregulation of 
E-cadherin expression is concomitant with the de novo expression of vimentin. The 
loss of adhesive function of E-cadherin may promote the dedifferentiation of 
epithelial cells to an invasive stage. All data considered, CaLu-1 cells are highly 
undifferentiated carcinoma cells expressing weak cell-cell junction proteins and are 
therefore more motile (Frixen UH et al., 1991). This may lead to a rather 
mesenchymal and invasive phenotype.  
 
 
 Human Lung Cancer Cell Lines embedded in ECM as Organoids: Pheno-4.1.2
typic Characterization using Phase-contrast Microscopy  
As illustrated in Figure 14 upon cultivation as organoids the surrounding ECM affects 
the microtumors’ proliferation, growth and in particular the invasive behavior. CaLu-1 
cells invaded already on day one the Matrigel-collagen type 1 matrix, followed by 
NCI-H1975 on day 8. Despite a small increase in diameter of the HCC827 
microtumors invasion was not observed for the cell lines HCC827 and NCI-H1437.  
 
 
 
 
 
 
 
 
 
 
Figure 14: Differential growth and 
invasive behavior of four different 
human lung cancer cell lines (phase-
contrast micrographs).  
Cells were cultivated as three-dimensional 
cell aggregates (spheroids) or embedded 
as organoids in Matrigel/collagen type 1 
scaffolds. All cell lines formed spheroids 
within 48h using the methylcellulose 
method (CaLu-1, 2000 cells; HCC827, 
2500 cells; NCI-H1437, 2000 cells; NCI-
H1975, 5000 cells). Embedded organoids 
were cultivated in matrix consisting of 
equal ratios of Matrigel and Collagen type 
1 for 1 day (CaLu-1), 8 days (NCI-H1975, 
NCI-H1437) and 9 days (HCC827). Bar, 
200 µm 
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A direct comparison of different ECM protein compositions revealed the physico-
chemical and biological impact of the matrix on the embedded spheroids, here 
referred as organoids. As an example two highly differentiated and mesenchymal 
lung cancer cell lines are shown. Even though all depicted cell lines originate from 
human lung epithelial malignancies the organoids showed significant differences in 
growth and invasion behavior. Spheroids of all four lung cancer cell lines were 
generated using poly-HEMA coated 96-well plates. Spheroids were harvested on the 
second day and embedded into different natural ECM scaffolds. These organoids 
were incubated then at 37°C and 5% CO2 in a humidified atmosphere for up to 11 
days. Images were acquired by phase-contrast microscopy.  
 
CaLu-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Growth and invasive behavior of human lung cancer cell line CaLu-1 in Matrigel 
matrices (phase-contrast micrographs).  
Spheroids were generated using poly-HEMA coated flat bottom 96-well plates. Organoids were 
embedded in different matrices consisting of 33% and 85% v/v Matrigel diluted with growth medium 
or in undiluted (100% v/v) Matrigel matrix. Organoids were cultivated for 9 days under common 
culture conditions. An increase in Matrigel concentration correlated with higher invasiveness of the 
microtumors on day 9. Bar, 200 µm.  
Matrigel™ 
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Figure 16: Growth and invasive behavior of 
human lung cancer cell line CaLu-1 in 
collagen Type 1 matrices (phase-contrast 
micrographs).  
Spheroids were generated using poly-HEMA 
coated flat bottom 96-well plates. Organoids 
were embedded in different matrices consisting 
of 1.3 – 2.9 mg/mL collagen type 1 concentration 
diluted with growth medium; or in undiluted 
collagen matrix (3.7 mg/mL). Organoids were 
cultivated for 5 days under common culture 
conditions. Invasion of microtumors could be 
observed at collagen concentrations between 1.3 
- 2.9 mg/mL. Bar, 200 µm. 
Collagen type 1 
Figure 17: Growth and invasive behavior of 
human lung cancer cell line CaLu-1 in 
Matrigel/collagen Type 1 matrices (phase-
contrast micrographs).  
Spheroids were generated using poly-HEMA 
coated flat bottom 96-well plates. Organoids 
were embedded into Matrigel/collagen type 1 
matrices consisting of 66% and 85% v/v 
Matrigel/collagen matrix diluted with growth 
medium; or undiluted (100% v/v) 
Matrigel/collagen matrix and cultivated for 5 days 
under common culture conditions. The matrix 
composed of equal amounts of Matrigel and 
collagen. Invasion of microtumors could be 
observed at all matrix concentrations.  
Bar, 200 µm.  
Matrigel™ / Collagen type 1 
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CaLu-1 organoids were able to invade into all ECM scaffolds regardless of 
composition except 3.7 mg/mL collagen type 1 concentration. When CaLu-1 
organoids are embedded into Matrigel matrix they showed different invasion 
behavior depending on the matrix composition. In collagen type 1 matrices CaLu-1 
organoids exhibited the highest invasion rate in all concentrations between 1.3 and 
2.9 mg/mL collagen already on day 1. In matrices composing of Matrigel/collagen 
type 1 mixtures CaLu-1 organoids showed invasion characteristics similar to 
collagen type 1 matrices (Figures 15-17).  
 
 
HCC827 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Growth and invasive behavior of 
human lung cancer cell line HCC827 in 
Matrigel matrices (phase-contrast 
micrographs).  
Spheroids were generated using poly-HEMA 
coated flat bottom 96-well plates. Organoids 
were embedded in different matrices consisting 
of 33% and 85% v/v Matrigel diluted with growth 
medium or in undiluted (100% v/v) Matrigel 
matrix. Organoids were cultivated for 7 days 
under common culture conditions.  
Bar, 200 µm.  
Matrigel™ 
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Figure 19: Growth and invasive behavior of 
human lung cancer cell line HCC827 in 
collagen type 1 matrices (phase-contrast 
micrographs). 
Spheroids were generated using poly-HEMA 
coated flat bottom 96-well plates. Organoids 
were embedded in different matrices consisting 
of 1.3 – 2.9 mg/mL collagen type 1 concentration 
diluted with growth medium; or in undiluted 
collagen matrix (3.7 mg/mL). Organoids were 
cultivated for 7 days under common culture 
conditions. Bar, 200 µm.  
Collagen type 1 
Figure 20: Growth and invasive behavior of 
human lung cancer cell line CaLu-1 in 
Matrigel/collagen Type 1 matrices (phase-
contrast micrographs).  
Spheroids were generated using poly-HEMA 
coated flat bottom 96-well plates. Organoids 
were embedded into Matrigel/collagen type 1 
matrices consisting of 66% and 85% v/v 
Matrigel/collagen matrix diluted with growth 
medium; or undiluted (100% v/v) 
Matrigel/collagen matrix and cultivated for 5 days 
under common culture conditions. The matrix 
composed of equal amounts of Matrigel and 
collagen. Invasion of microtumors could be 
observed at all matrix concentrations	   but the 
morphology of the invasive cells was different .  
Bar, 200 µm.  
 
Matrigel™ / Collagen type 1 
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HCC827 organoids were only able to weakly invade into ECM scaffolds consisting of 
collagen type 1 protein. Embedded into Matrigel and Matrigel/collagen type 1 
matrices, HCC827 organoids showed no significant invasive behavior. In collagen 
type 1 matrices HCC827 organoids showed the highest invasion rate in all 
concentrations between 1.3 and 2.9 mg/mL collagen (Figures 18-20). HCC827 
organoids were able to grow in all matrices regardless of composition.  
 
NCI-H1437 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
Figure 21: Growth and invasive behavior of human lung cancer cell line NCI-H1437 in Matrigel matrices 
[Panel A], and collagen type 1 matrices [Panel B] (phase-contrast micrographs).  
Spheroids were generated using poly-HEMA coated flat bottom 96-well plates. Organoids were embedded in 
different matrices consisting of 33% and 85% v/v Matrigel diluted with growth medium or in undiluted Matrigel 
matrix (A) and in collagen type 1 matrices consisting of 1.3 – 2.9 mg/mL collagen type 1 concentration (B) 
diluted with growth medium; or in undiluted collagen matrix (3.7 mg/mL). Organoids were cultivated for 11 days 
under common culture conditions. Bar, 200 µm.  
 
Matrigel™ Collagen type 1 
Results/Phenotypic Characterization of Lung Cancer Cell Lines 
 
 
Nico Jacobi  72/111 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NCI-H1437 organoids were only able to invade into ECM scaffolds consisting of 85% 
v/v Matrigel/collagen matrix diluted with growth medium; and undiluted (100% v/v) 
Matrigel/collagen matrix. Embedded into Matrigel or collagen type 1 matrices,  
NCI-H1437 organoids showed no invasive behavior (Figures 21, 22). NCI-H1437 
organoids were able to grow in all matrices regardless of composition.  
 
 
NCI-H1975 
 
NCI-H1975 organoids were able to invade into ECM scaffolds consisting of collagen 
type 1 protein. Embedded into matrices consisting of 85% v/v Matrigel/collagen 
matrix diluted with growth medium; and undiluted (100% v/v) Matrigel/collagen 
matrices NCI-H1975 organoids showed moderate invasive behavior (Figures 23, 24). 
In matrices consisting of 66% v/v Matrigel/collagen, NCI-H1975 organoids exhibited 
the most significant increase in average diameter.  
 
Figure 22: Growth and invasive behavior of human lung 
cancer cell line NCI-H1437 in Matrigel/collagen type 1 
matrices (phase-contrast micrographs).  
Spheroids were generated using poly-HEMA coated flat bottom 
96-well plates. Organoids were embedded in different matrices 
consisting of 66% and 85% v/v Matrigel/collagen matrix diluted 
with growth medium; or undiluted (100%) Matrigel/collagen matrix. 
Organoids were cultivated for 11 days under common culture 
conditions. The matrix composed of equal amounts of Matrigel 
and collagen. Bar, 200 µm.  
Matrigel™ / Collagen type 1 
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A B 
Figure 23: Growth and invasive behavior of human lung cancer cell line  
NCI-H1975 in Matrigel matrices [Panel A], and collagen type 1 matrices [Panel B] (phase-contrast micrographs).  
Spheroids were generated using poly-HEMA coated flat bottom 96-well plates. Organoids were embedded in different 
matrices consisting of 33% and 85% v/v Matrigel diluted with growth medium or in undiluted Matrigel matrix (A) and in 
collagen type 1 matrices consisting of 1.3 – 2.9 mg/mL collagen type 1 concentration (B) diluted with growth medium; or 
in undiluted collagen matrix (3.7 mg/mL). Organoids were cultivated for 6 (A) or 8 (B) days under common culture 
conditions. Bar, 200 µm.  
Matrigel™ Collagen type 1 
Figure 24: Growth and invasive behavior of human lung cancer cell line 
NCI-H1975 in Matrigel/collagen type 1 matrices (phase-contrast 
micrographs).  
Spheroids were generated using poly-HEMA coated flat bottom 96-well 
plates. Organoids were embedded in different matrices consisting of 66% 
and 85% v/v Matrigel/collagen matrix diluted with growth medium; or 
undiluted (100% v/v) Matrigel/collagen matrix. Organoids were cultivated for 
8 days under common culture conditions. The matrix composed of equal 
amounts of Matrigel and collagen. Bar, 200 µm. 
Matrigel™ / Collagen type 1 
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 Marker Protein Expression in 3D: Phenotypic Characterization using Con-4.1.3
focal Laser Scanning Microscopy  
 
So far we have characterized the lung cancer cell lines in terms of morphology and 
expression of epithelial differentiation markers when grown two-dimensionally. 
Additionally, we investigated the growth and invasion behavior of multi cellular tumor 
organoids (MCTO) embedded into different natural ECM scaffolds.  
To determine vitality and quality of cells within MCTOs we examined the expression 
of several epithelial markers. In addition we localized the regions of cell proliferation 
within organoids using Ki67 as a proliferation marker. For this we generated 
spheroids using the methylcellulose method. The matrix consisting of a mixture of 
Matrigel and collagen was evaluated in previous experiments as an ideal matrix for 
the majority of cell lines. Therefore the organoids were embedded in this matrix, 
fixed in 3% formaldehyde and processed for immunofluorescence microscopy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: Marker protein expression of human lung cancer cell line HCC827 in Matrigel/collagen type 1 matrices 
(confocal laser scanning micrographs).  
Spheroids were generated using poly-HEMA coated flat bottom 96-well plates. Organoids were embedded in 
Matrigel/Collagen matrix consisting of 66% v/v Matrigel/collagen matrix diluted with growth medium. Confocal laser scanning 
micrographs of horizontal optical sections show the distribution of E-cadherin, β-catenin, Ki67 and integrin β 1 in 
formaldehyde fixed organoids after immunofluorescent staining. Bars, 75 µm.  
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We could show in immunofluorescent (IF) micrographs that the cells within organoids 
are alive and show typical marker expression. This finding correlates with previous 
apoptosis assays using Annexin V (Kalod R, 2011). The immunostaining allowed 
also for marker staining of cells residing in the very center of organoids larger than 
200 µm in diameter (Figure 25). We therefore could demonstrate that IF staining 
might be a suitable method to detect alterations in protein expression, apoptosis and 
necrosis that may result from drug treatment.  
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 RNA Expression Profiling in 2D vs. 3D: Affymetrix Gene Chip 4.2
Technology 
 
The pattern of gene expression within a cell determines the cell’s phenotype and 
function. Exploiting cDNA microarray technology provided insight of global gene 
expression of the NSCLC cell lines CaLu-1, HCC827, NCI-H1437 and NCI-H1975. 
We compared the cell lines’ transcriptomes when grown as a monolayer with those 
of organoids embedded in Matrigel/collagen type I matrices. The composition of the 
used matrix was evaluated in previous experiments for all cell lines. This was 
determined with regard to growth, proliferation and invasion of the embedded 
organoids.  
 
For 2D RNA samples cells were seeded before RNA preparation onto 100 mm 
culture dishes. For 3D RNA samples the spheroids were generated using the rotary 
cell culture bioreactor. For RNA preparation the QIAgen’s miRNeasy Mini Kit 
containing Trizol was used. RNA quality determination via capillary gel 
electrophoresis using the Experion™ Platform (Bio-Rad, Figure 26) was performed 
and the RNA samples were frozen (-80°C) until further processing. After establishing 
cDNA from the RNA samples the expression profiling was performed using 
Affymetrix gene chips (Affymetrix Inc., Table 6 A, B).  
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A 
B 
Figure 26: Preliminary RNA quality tests using the capillary gel electrophoresis platform Experion™ 
and Experion RNA StdSens Analysis Kit (BioRad).  
A| Virtual gel showing RNA bands of different dilutions of 2D and 3D cell lysates of HCC827 and NCI-H1975 
cell lines.  
B| Electropherogram of a 3D sample (NCI-H1975, Matrigel/Collagen) with a lower marker peak at 22sec, a 5S 
rRNA peak at 25sec, a 18S rRNA peak at 40sec and a 28S rRNA peak at 47sec. The results table below 
includes the RNA concentration and the ratio between 28S and 18S as an indicator for RNA integrity 
(theoretically ≤ 2.7, normally 1.2-1.95). The RNA Quality Indicator (RQI) allows to standardize and quantitate 
RNA integrity (10 “intact” to  1 “fully degraded”). 
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The GeneChip human mapping assay (Affymetrix) was used to provide genome-
wide data on gene expression patterns. We investigated how gene expression in the 
lung adenocarcinoma cell lines HCC827 and NCI-H1975 is altered due to 3D 
Gene	  Name Localisation Fold	  Change
small	  nucleolar	  RNA,	  H/ACA	  box	  75 2q37.1 5,0
ribonuclease,	  RNase	  A	  family,	  4 14q11.1 4,5
similar	  to	  cleavage	  stimulation	  factor,	  3	  pre-­‐RNA,	  subunit	  2 -­‐ 4,1
serpin	  peptidase	  inhibitor,	  clade	  B	  (ovalbumin),	  member	  4 18q21.3 3,8
matrix	  metallopeptidase	  13	  (collagenase	  3) 11q22.3 3,8
triggering	  receptor	  expressed	  on	  myeloid	  cells	  1 6p21.1 3,6
stanniocalcin	  1 8p21-­‐p11.2 3,6
ADAM	  metallopeptidase	  domain	  28 8p21.2 3,2
serpin	  peptidase	  inhibitor,	  clade	  A	  (antitrypsin),	  member	  3 14q32.1 3,2
angiogenin,	  ribonuclease,	  RNase	  A	  family,	  5 14q11.1-­‐q11.2 3,2
putative	  binding	  protein	  7a5 7p15.3 5,2
small	  nucleolar	  RNA,	  C/D	  box	  28 11q13 3,9
similar	  to	  60S	  ribosomal	  protein	  L22	  (Heparin-­‐binding	  protein	  HBp15) 2q13 3,8
alanyl	  (membrane)	  aminopeptidase	  (aminopeptidase	  N) 15q25-­‐q26 3,7
small	  nucleolar	  RNA,	  C/D	  box	  18A 15q22 3,5
small	  nucleolar	  RNA,	  C/D	  box	  26 11q13 3,4
RNA,	  small	  nucleolar 11q23.3-­‐q25 3,4
small	  nucleolar	  RNA,	  C/D	  box	  56 20p13 3,2
small	  nucleolar	  RNA,	  H/ACA	  box	  29 6q25.3 3,2
similar	  to	  nuclear	  protein	  in	  testis 10q23.2 3,2
3D	  higher	  
than	  2D
2D	  higher	  
than	  3D
NCI-­‐H1975	  2D	  on	  Matrigel	  Coating	  2D	  vs.	  3D	  in	  Matrigel/Collagen	  Matrix
Gene	  Name Localisation Fold	  Change
serum	  amyloid	  A1 11p15.1 28,1
small	  nucleolar	  RNA,	  C/D	  box	  61 Xq26.3 9,1
lipocalin	  2	  (oncogene	  24p3) 9q34 9,0
ceruloplasmin	  (ferroxidase) 3q23-­‐q25 8,1
V-­‐set	  and	  immunoglobulin	  domain	  containing	  1 Xq22.3 7,9
chemokine	  (C-­‐C	  motif)	  ligand	  20 2q33-­‐q37 7,3
complement	  factor	  H 1q32 7,0
complement	  factor	  B 6p21.3 6,9
interferon,	  alpha-­‐inducible	  protein	  27 14q32 6,1
transcobalamin	  I	  (vitamin	  B12	  binding	  protein,	  R	  binder	  family) 11q11-­‐q12 6,0
small	  nucleolar	  RNA,	  C/D	  box	  38B 1p34.1-­‐p32 8,3
small	  nucleolar	  RNA,	  C/D	  box	  59B 12q13.3 5,7
kallikrein-­‐related	  peptidase	  6 19q13.3 5,0
bicaudal	  C	  homolog	  1	  (Drosophila) 10q21.1 5,1
small	  nucleolar	  RNA,	  C/D	  box	  117 6p21.33 4,6
pleckstrin	  homology-­‐like	  domain,	  family	  B,	  member	  2 3q13.2 4,5
ribosomal	  protein	  SA 3p22.2 4,5
erythrocyte	  membrane	  protein	  band	  4.1-­‐like	  2 6q23 4,4
small	  nucleolar	  RNA,	  C/D	  box	  28 11q13 4,4
small	  nucleolar	  RNA,	  C/D	  box	  25 11q13 4,3
3D	  higher	  
than	  2D
2D	  higher	  
than	  3D
HCC827	  2D	  on	  Matrigel	  Coating	  vs.	  3D	  in	  Matrigel/Collagen	  Matrix
A 
B 
Table 6: Selected changes in gene expression of HCC827 and NCI-H1975 lung cancer cell 
lines cultured as a monolayer on Matrigel coating or as MCTOs in Matrigel/Collagen Matrix.  
The list contains ten differentially expressed genes, and their chromosmal localisation, in HCC827 
cells (A) and NCI-H1975 cells (B) arranged according to their fold change. 
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cultivation. The expression of approximately 35.500 genes was analyzed and ten 
differentially expressed genes are boxed (Table 6 A, B).  
 
Microarray Analysis  
The highest differentially expressed gene encodes for serum amyloid A 1 (SAA1), an 
apolipoprotein which is produced in the liver. We could show a 28-fold up-regulation 
of SAA1 in MCTOs of adenocarcinoma cell line HCC827 compared to monolayer 
culture on Matrigel coated plates. An up-regulation of this inflammatory protein in 
renal cell carcinomas was reported to increase the expression of metalloproteinase 
(MMP)-9 and hence the invasive behavior of tumor cells (Paret C et al., 2010).  
Lipocalin 2 (NGAL) plays an important role in the transport of lipophilic ligands such 
as progesterone and prostaglandin. It is part of MMP-9 complex in human 
neutrophils where it protects MMP-9 and preserves MMP-9 activity. NGAL mediates 
inflammation, is up-regulated in many cancers and was reported to stimulate tumor 
growth in breast cancer (Fernández CA et al., 2005). We found a 9-fold up-regulation 
of Lipocalin 2 in HCC827 MCTOs compared to monolayer cultured cells.  
Genes encoding for immunomodulatory proteins that serve as protectors from 
complement mediated lysis, such as complement factor B and H, are up-regulated 
(7-fold) in MCTOs of HCC827 cell line.  
Ovalbumin, a peptidase inhibitor, is 4-fold up-regulated in NCI-H1975 MCTOs 
compared to monolayer culture. This inhibitor is often highly expressed in tumors 
originating from GI tract, the lung and thyroid. 30-50% of adenocarcinomas strongly 
express ovalbumin (Heighway J et al., 2004).  
Beside altered expression of protein encoding genes a remarkable number of genes 
encoding for small nucleolar RNAs (snoRNAs) are differentially expressed in MCTOs 
compared to monolayer cultured cells. Since snoRNAs are non-coding RNAs that 
might regulate cell fate they could consequently contribute to oncogenesis as 
reviewed very recently (Williams GT and Farzaneh F, 2012). Apart from their known 
function as guide RNAs for the post-transcriptional modification of ribosomal RNAs, 
only little is known about their role in diseases like cancer. The EGFR expression in 
HCC827 cells which carry a 10-fold amplification mutation is 2-fold higher in 
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monolayer cell culture than in organoids. No significant difference in EGFR gene 
expression was observed for the NCI-H1975 cell line.  
Upcoming pathway analyses using the Ingenuity software (Ingenuity Systems) will 
help to decipher signaling pathways specifically activated or inhibited in 3D.  
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 Differential Phosphorylation Patterns in 2D vs. 3D: Proteome 4.3
Profiler Antibody Array™  
 
A frequent reversible post-translational modification that plays a central role in 
tumorigenesis is phosphorylation. For this purpose it is essential to determine the 
phosphorylation patterns of crucial signaling molecules associated in tumorigenesis 
(Mann M and Jensen ON, 2003).  
By using Proteome Profiler Antibody Arrays™ (R&D Systems) we determined the 
phosphorylation state of proteins involved in:  
 
• RTK signaling 
• MAPK signaling 
• Phosphokinase signaling 
• Apoptosis 
 
We compared the cell lines’ phosphorylation patterns when grown as a monolayer 
with those of organoids embedded in Matrigel/collagen type I matrices.  
 
For 2D samples cells were seeded before phospho-profiling onto 100 mm culture 
dishes. For 3D samples, spheroids were generated using poly-HEMA coated 96-well 
plates and embedded in Matrigel/collagen Type 1 matrices. The cells and organoids 
were processed for phospho-proteome analyses according to manufacturer’s 
instructions (see Material and Methods). The cells were lysed, added to the 
membranes and incubated. The secondary anti-phospho-tyrosine-HRP antibody was 
added and chemiluminescent western blotting substrate was applied. The signal was 
detected by a ChemiDoc XRS platform. For normalization of cell number western 
blots against actin and RPLP0 were performed with 2D and 3D lysates. For CaLu-1 
cells it was additionally normalized for total EGFR which brought the same result as 
actin.  
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Figure 27: Determination of differential phosphorylation patterns in lung cancer cell lines using receptor 
tyrosine kinase (RTK) antibody arrays.  
A| Phosphorylated proteins in the lysates of cells grown as a monolayer (2D) or organoids embedded in 
Matrigel/collagen matrices (3D) were detected on antibody arrays via chemiluminescence. B| Relative levels of 
tyrosine phosphorylation of RTK related proteins in 2D and 3D. RTKs are significantly more abundant in 3D culture 
compared to cell monolayer. C| Actin for normalization of cell numbers in 2D and 3D.  
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Data from RTK array are shown in Figure 27. For normalization of cell number 
western blots against actin and RPLP0 were assessed in 2D and 3D lysates. For 
CaLu-1 also total EGFR levels were measured for normalization which showed same 
results. We could demonstrate that the phosphorylation of RTK related proteins is 
higher in organoids compared to cell monolayer. Exclusively in lysates of the cell line 
NCI-H1975 a relatively balanced 2D/3D expression of phospho-proteins was 
observed. The crucial role of epidermal growth factor receptor 1 (EGFR, ErbB1) in 
lung cancer has been discussed earlier. RTK Antibody Arrays™ revealed a 
significant overexpression (47-fold) of a phosphorylated form of this receptor in 
CaLu-1 organoids compared to conventional cell monolayer. This finding correlates 
strongly with the proliferative and metastatic potential of this cell line as MCTOs that 
was already determined microscopically. Furthermore we detected higher levels of 
pEGFRs in organoids in all other investigated cell lines as well (2-fold NCI-H1975; 9-
fold HCC827; 13-fold NCI-H1437). While ErbB1 binds ligands (e.g. EGF, TGF-α, 
Amphiregulin) and directly relays signals via autophosphorylation of its intracellular 
domain into the cell ErbB2 and ErbB3 are non-autonomous. ErbB2 lacks the 
capacity to bind a growth-factor ligand and ErbB3 feature a defective kinase activity. 
Despite this fact, ErbB2 and ErbB3 form heterodimeric complexes with other family 
members to generate ErbB signaling (Citri A and Yarden Y, 2006). We could 
demonstrate that ErbB2 and ErbB3 were highly phosphorylated in MCTOs. It was 
reported that hyperactivated EGFR signaling mediates anti-apoptotic and pro-
survival signals through Ras-Raf-MEK, ERK1 and ERK2, PI3K–Akt and STAT3 and 
STAT5 pathways (Sharma SV et al., 2007). We could demonstrate that MEK1/2, 
ERK1, Akt and STAT3/5 are significantly more phosphorylated in MCTOs of different 
cell lines than in monolayer cultures (Table 7). It has been reported that STAT3, 
regulate genes for anti-apoptosis, pro-proliferation, angiogenesis, and metastasis 
(Yu H et al., 2009). We determined an 11-fold increase of STAT3 Y705 in NCI-
H1437 MCTOs compared to conventional monolayer.  
The phosphoinositide signaling system is a crucial regulator of most cellular 
processes. In this system phospholipase C gamma (PLCγ) acts as a key enzyme in 
the phosphoinositide signaling, especially in cancer. In mammary tumor cells it has 
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been demonstrated that PLCγ regulates cancer cell motility under the control of EGF 
(Bunney TD and Katan M, 2010). We detected an 18-fold increase of PLCγ1 
phosphorylation at Y783 in the NCI-H1437 cell line when cultured as MCTOs.  
 
A comprehensive overview of phospho-proteome profiles of the four lung cancer cell 
lines in 2D and 3D is depicted below (Table 7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7: Fold changes of various phospho-protein patterns dependent of cultivation method of four lung cancer cell lines 
using phospho-antibody arrays.  
Fold change of proteins involved in phosphorylation of RTK (A), MAPK (B) Phospho-Kinase (C) and Apoptosis (D) related proteins 
in 2D and 3D. The values in the 3D box indicate the fold changes of phosphorylation of a certain protein in comparison to 2D and 
vice versa. 
C D 
A B 
 Results/Chemotherapeutic and Molecularly Targeted Treatment 
 
Nico Jacobi  85/111 
 Chemotherapeutics and Molecularly Targeted Treatment: Drug-4.4
Response of 3D-Cultured Tumor Cells in Comparison to 2D-
Cultured Cells 
We already demonstrated that 3D cell cultivation significantly influences gene 
expression and particularly phosphorylation of EGFR related signaling molecules. 
We hypothesized earlier that EGFR mutations and amplifications could be an 
indication for oncogene addiction of the mutation carrying cell lines. These mutations 
consequently alter cell morphology, behavior and could lead to an increased 
sensitivity to the EGFRI Gefitinib. The huge differences in the phosphorylation 
patterns between cells grown two-dimensionally and MCTOs might therefore be 
essential to be considered by evaluating drug candidates in vitro. 
Since drug sensitivity and gene expression are strongly interdependent we 
determined the relationship between three-dimensional cultivation and therapeutic 
efficacy of anti-cancer agents. We used alamarBlue® reagent to determine cell 
viability dependent on the ability of living cells to reduce resazurin to resorufin 
producing red fluorescence (O’Brien J et al., 2000).  
 
 
 Chemotherapeutic Treatment 4.4.1
For monolayers cells were seeded in 96-well microtiter plates. Poly-HEMA coated 
96-well microtiter plates were used for spheroid generation. For organoids the 
spheroids were embedded in Matrigel/collagen matrices. 96h after treatment, 
alamarBlue® was added and incubated for 6h at 37°C. Data were assessed using 
the PARADIGM™ Detection Platform and the appropriate detection cartridge at 595 
nm.  
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Figure 28: Response to paclitaxel of 3D-cultured tumor cells in comparison to 2D-cultured Cells.  
Experiments were performed in 96-well microtiter plates. Cells were individually treated with different concentrations of 
paclitaxel for 96h. Cell survival was determined with alamarBlue® reagent (6h at 37°C). Data assessment by 
PARADIGM™ multimode reader. Curve fitting, graphing and calculation of EC50 values by the biostatistic software 
GraphPad Prism 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
After paclitaxel treatment HCC827 showed similar drug responses independent on 
culturing method. However, the drug sensitivity slightly increased when the cells 
were cultured in 3D. CaLu-1 and NCI-H1975 cells grown in 2D showed a significant 
increase in survival compared MCTOs. This exemplifies the problematic nature of 
drug screening exclusively on monolayer cultures. Drug candidates that might have 
beneficial effects in vivo would not be identified (Figure 28).  
 
Microscopic Examination of the Chemotherapeutic Effect of Paclitaxel on 
CaLu-1 microtumors| So far we have shown in the previous figure that paclitaxel 
treated CaLu-1 cells showed an increase in survival upon 3D cultivation compared to 
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2D-grown cells. AlamarBlue® reagent only allows detecting variances in the 
respiratory chain of cells being an indicator for cell viability. Due to that we performed 
additional phase-contrast imaging of paclitaxel treated CaLu-1 organoids to show 
phenotypic alterations due to this toxic agent.  
 
After 96h of paclitaxel treatment, images of microtumors were acquired by phase-
contrast microscopy. A classical morphology of adenocarcinoma is the cordlike 
infiltration pattern with Indian-file formation (Sternberg S, 2004). With increasing 
paclitaxel concentration these infiltration branches were significantly reduced  
(Figure 29). This might be due to paclitaxel mediated distortion of microtubule 
depolymerization which is important for matrix invasion. Despite this drastic effect on 
the invasive behavior, the survival of CaLu-1 organoids was not affect by paclitaxel 
as determined previously (Figure 28).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: Therapeutic effect of the drug paclitaxel on the invasive potential of 
human lung cancer cell line CaLu-1 in Matrigel/collagen type 1 matrices 
(phase-contrast micrographs).  
Spheroids were formed within 48h using poly-HEMA coated flat bottom 96-well 
plates. Organoids were embedded after 5 days in Matrigel/Collagen matrix 
consisting of 66% v/v Matrigel/collagen matrix diluted with growth medium. Phase-
contrast micrographs show the paclitaxel dependent inhibition of invasion of CaLu-1 
MCTOs after 96h of treatment. Bar, 200 µm.  
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The Chemotherapeutic Effect of Cis-Diamminedichloroplatinum| Cisplatin (Cis-
Diamminedichloroplatinum II, Cis-DDP) treatment elicited comparable cytotoxic 
effects on 2D and 3D cultured cells. Only at very high concentrations (>100 µM) we 
observed a probably drug-unrelated cytotoxicity resulting in cell death of all four cell 
lines (Figure 30). The different modes of action of paclitaxel and Cis-DDP could be 
an explanation for this effect. While paclitaxel interferes with microtubule formation 
Cis-DDP binds to the DNA and thereby elicits its genotoxic effect.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30: Response to Cisplatin of 3D-cultured tumor cells in comparison to 2D-cultured Cells.  
Experiments were performed in 96-well microtiter plates. Cells were individually treated with different concentrations of 
Cisplatin for 96h. Cell survival was determined with alamarBlue® reagent (6h at 37°C). Data assessment by 
PARADIGM™ multimode reader. Curve fitting, graphing and calculation of EC50 values by the biostatistic software 
GraphPad Prism 5. 
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 Targeted Therapies 4.4.2
Two of the four used cancer cell lines carry well described EGFR mutations while the 
other two cell lines express wild-type EGFRs. The impact of three-dimensionality on 
EGF signaling in these cells can therefore be evaluated in this model. To block EGF 
signaling the cells were treated with the EGFR inhibitor Gefitinib.  
Cells (15000) were treated with Gefitinib for 96h and subsequently viable cells were 
quantified by alamarBlue® assay. Data were assessed using the PARADIGM™ 
Detection Platform and the appropriate detection cartridge at 595 nm (Figure 31).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31: Response to Gefitinib of 3D-cultured cells in comparison to 2D-cultured cells.  
Lung adenocarcinoma cells (CaLu-1, HCC827, NCI-H1437 and NCI-H1975) were grown as monolayer, spheroids or 
embedded organoids in 96-well microtiter plates. The cells were treated with different concentrations of Gefitinib for 
96h. Viable cells were quantified with alamarBlue® reagent. Data assessment was performed by PARADIGM™ 
multimode reader. Curve fitting, graphing and calculation of EC50 values by the biostatistic software  
GraphPad Prism 5.  
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HCC827| Most significant is the decrease in survival at the highest drug 
concentration (10 µM) when the cells are cultured as spheroids (9%) compared to 
organoids (22%) and monolayer culture (61%).  
 
 
NCI-H1975| This cell line carries the drug sensitive point mutation, L858R, to HER1 
inhibitors and a T790M point mutation which is associated with acquired drug 
resistance to Erlotinib or Gefitinib (Lynch TJ et al., 2004). Under conventional 
monolayer conditions NCI-H1975 cells were resistant to Gefitinib treatment. When 
grown three-dimensionally the cells’ survival rates decreased down to 35% as 
spheroids and 5% as organoids.  
 
Differential Proliferation of Lung Cancer Cell Lines in 2D and 3D 
Many anti-cancer therapies are strongly dependent on the aberrantly up-regulated 
proliferation of malignant cells. Therefore we determined differential proliferation 
behavior of cells grown as a monolayer compared to multi cellular tumor spheroids 
(Figure 15). In both growth conditions NCI-H1437 cell line reached highest cell 
density followed by NCI-H1975 cell line. Grown two-dimensionally CaLu-1 and 
HCC827 cells reached a plateau after 12 days. After longer growth periods the 
proliferation curves of all cell lines cultured as spheroids started to flatten out and 
experienced a decline (CaLu-1, day 8; HCC827, day 6; NCI-H1437 and NCI-H1975 
day 14). This was due to the onset of disintegration of the spheroids after prolonged 
incubation without being embedded. Therefore cell counting was stopped after 12 
days (HCC827, CaLu-1) or 16 days (NCI-H1437, NCI-H1975). No increased 
apoptotic rates were observed in 2D and 3D cultures using in situ Annexin V assay 
(Kalod R, 2011).  
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These findings indicate that the Gefitinib related cytotoxicity (Figure 31) is not 
interrelated with an increased proliferation but with EGFR oncogene addiction 
especially found in HCC827 cells.  
 
A B 
Figure 32: In vitro proliferation of a monolayer (A) or multi cellular tumor spheroids (B) of 4 human lung cancer 
cell lines.  
Monolayer – 3000 cells were seeded per well of a flat bottom 96-well plate.  Spheroids – using the methylcellulose 
method, 3000 cells were seeded per well of a round bottom 96-well plate. The cells and multicellular tumor spheroids 
(MCTS) were grown in defined growth media at 37°C and 5% CO2 in a humidified atmosphere. In two-day-intervals the 
cells were harvested by trypsinization for determining cell number and viability (Neubauer counting chamber, Trypan 
Blue). Growth medium was replaced twice and in later stages of the experiment three times a week.
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 Differentially Labeled Cell Types: Track the Cells’ Fates in Het-4.5
erotypic Co-Cultures  
 
Apart from cancer cells a substantial part of solid tumors is made up by stromal cells 
such as fibroblasts, lymphocytes, macrophages, dendritic cells and other myeloid 
cells. The fine-tuned crosstalk between cancer cells and their surrounding 
microenvironment must be taken into consideration in order to evaluate drugs more 
reliable. Therefore it is essential to monitor the drug’s effects on cancer cells and 
stromal cells likewise. To track the fate of each individual cell type within a 
heterotypic co-culture we lentivirally transduced cancer cells and stromal cells to 
stably express fluorescent proteins (LentiORF™ system, Thermo Fisher Scientific).  
 
Three-Dimensional Co-Culture of Lung Cancer Cell Line HCC827 and 
Neonate Human Fibroblasts  
 
Beside matrix related effects cellular crosstalk between tumor and stromal cells is a 
crucial factor in tumorigenesis. It is commonly accepted that stromal cells such as 
cancer-associated fibroblasts support tumor cells by fostering tumor invasion 
(Burdett E et al., 2010). Co-culture of lung cancer cells with fibroblasts reveals the 
supportive characteristic of stromal cells on the cancer cells.  
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The proliferative and invasive potential of lung cancer cell line HCC827 in 
Matrigel/collagen type 1 matrices was previously characterized (Figure 20). 
Embedded into Matrigel/collagen type 1 matrices, HCC827 organoids showed no 
significant invasive behavior. Upon co-cultivation with fibroblasts HCC827 cells 
showed high invasive potential. Already on day 6 first infiltration branches pointing 
towards fibroblasts are detectable (arrows, Figure 33). On day 12 the MCTO is 
almost completely deformed and interacts with the fibroblasts.  
 
 
Figure 33: Co-culture of lentivirally transduced lung cancer cell line HCC827 
and neonate human dermal fibroblasts (confocal laser scanning 
micrographs).  
Both cell types were transduced using the lentiviral system LentiORF™. Tumor 
spheroids were generated using poly-HEMA coated round bottom 96-well plates. 
Organoids were embedded in 66% v/v Matrigel/collagen matrix in 96-well plates. 
40.000 fibroblasts were co-embedded to generate heterotypic co-cultures. 
Confocal laser scanning micrographs were taken in 72h intervals. Images show 
the effect of fibroblasts on the invasive behavior of HCC827 MCTOs (arrows).  
Bar, 300 µm.  
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 Discussion 5
The development of the first high-throughput cancer cell line screening program, the 
US National Cancer Institute 60 anti-cancer drug screen (NCI60), started in 1986. 
Since then the classical preclinical anti-cancer drug-screening strategies involved the 
growth of cancer cell lines as monolayers on tissue culture plastic combined with 
high-throughput screenings. Despite invaluable advances yielded by this 
methodology cells grown as monolayers remain poor predictors of drug efficacy and 
safety. It remained elusive whether a new compound will succeed as a potent anti-
cancer drug in the clinic or ultimately fail. Reasons for that might be the absence of 
crucial environmental cues. Stromal cells, vasculature, 3D architecture, ECM and 
environmental stimuli such as growth factors or physico-chemical parameters 
(rigidity, fluid dynamics, etc.) found within tissues strongly impact tumorigenesis 
(Burdett E et al., 2010). As a consequence these environmental cues are obviously 
crucial elements of reliable cancer models.  
 
Animal models are to date, a potent tool to study human cancer cells as 
subcutaneous, orthotopic or autochthonuos xenografts (Killion J.J. et al., 1999; 
Talmadge J.E et al., 1986). Although these models provide tumor cells with a 
number of three-dimensional cues that are absent during monolayer growth they 
suffer from some inherent drawbacks. The complexity, difficulty, high expenditures of 
animal experiments and influences of the murine tumor stroma adversely affect the 
evaluation of drug efficacy. These drawbacks might relegate animal tumor models to 
a secondary role in the preclinical drug screening in near future.  
 
To overcome shortcomings of classical cancer models in drug discovery, the 
development of complex three-dimensional cell-based cancer models gathered pace 
in the last years. The human tumor spheroid is the by far most widely used tissue-
engineered tumor model. It might allow evaluating and identifying new anti-cancer 
agents more reliable than conventional cancer models. The aim of this study was to 
establish methods to generate 3D lung cancer models might be amenable to high-
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throughput drug screening (HTS). Furthermore, we aimed to find differences in gene 
expression and phosphorylation of crucial signaling molecules due to 3D cultivation, 
and analyzed the efficacies of targeted drugs and chemotherapeutics in selected 3D 
models and conventional 2D cultures.  
 
 Characterization of Lung Cancer Cell Lines  5.1
 Phase-contrast microscopy 5.1.1
We characterized four lung cancer cell lines in terms of morphology and marker 
protein expression when grown as monolayer, as spheroids and as multi cellular 
tumor organoids (MCTO) embedded in natural ECM scaffolds. We performed initial 
tests to choose an appropriate ECM to serve as a scaffold for the organoids. 
Matrigel™ and collagen type 1 are natural building blocks that can be used for the 
establishment of matrices that mimic the microenvironment of tumors. We used 
these components to analyze the differential growth behavior of multi cellular tumor 
organoids (MCTO) in matrices consisting of Matrigel™ or collagen type 1 and 
defined mixtures of those.  
We observed that the cell lines featuring a rather undifferentiated phenotype when 
grown as monolayers had a higher invasive potential as MCTOs as well. NCI-H1975 
and in particular CaLu-1 cells exhibited a more undifferentiated, mesenchymal 
phenotype and had an increased capability to invade the matrix. In contrast to that, 
the more differentiated, polarized carcinoma cell lines HCC827 and NCI-H1437 
showed no significant invasive potential. We further showed that the invasive 
potential of CaLu-1 and NCI-H1975 cell line increased upon adding collagen type 1 
to the matrix. Embedded in collagen type 1 matrices with collagen concentrations 
between 1.2 – 2.9 mg/mL these cell lines invaded the matrix most.  
Pier P. Delsanto and his group reported that undernourishment of cells is increased 
with the gel concentration. The inhibitory effect of the matrix on the cell invasiveness 
at concentrations above 2.9 mg/mL collagen may be ascribable to the prolonged 
development of a suitable nutrient uptake of tumor cells within a stressed matrix 
(Delsanto PP et al., 2004).  
 
Discussion 
 
 
 
Nico Jacobi  96/111 
 Confocal laser scanning microscopy 5.1.2
Using immunofluorescent staining we could show that the expression of the epithelial 
differentiation marker E-cadherin was high in all used carcinoma cell lines grown as 
monolayers except CaLu-1. It is commonly accepted that in epithelial cells the 
downregulation of E-cadherin expression and concomitant de novo expression of 
vimentin is a hallmark of EMT (Liu T et al., 2012). We could demonstrate that CaLu-1 
cells featured the highest expression levels of vimentin compared to all other 
investigated cell lines (Figure 13).  
 
It has been consistently demonstrated that physiological cell signaling and related 
morphological and functional cellular changes rely crucially on the attachment of 
cells to surrounding three-dimensional mesh-like fibers (Cukierman E et al., 2002).  
Epithelial polarization is strongly interwoven with the formation of desmosomes and 
adherens junctions and the expression of E-cadherin. The loss of E-cadherin and the 
de novo expression of vimentin in epithelial cells is a hallmark for the transition to a 
mesenchymal phenotype (Thiery JP and Sleeman JP, 2006). This process, which is 
collectively termed epithelial-mesenchymal transition (EMT), is correlated with the 
loss of cell polarity and the detachment of cells from the position within the epithelial 
sheet during progression. Therefore EMT results in increased motility leading to 
tumor metastasis and a bad prognosis (Eger et al., 2004; Brabant G et al., 1993; Liu 
LK et al., 2010; Wirtz D et al., 2011). We could show that two differentiation markers 
that are known to control epithelial polarization are aberrantly regulated, resulting in 
different phenotypes among the four lung cancer cell lines (Figures 12, 13).  
 
 Differential Proliferation of Lung Cancer Cell Lines: 2D vs. Spheroids 5.1.3
 
Many anti-cancer therapies such as chemotherapies strongly depend on the 
sustained proliferation of malignant cells. Therefore we determined differential 
proliferation behavior of the cell lines grown as a monolayer compared to spheroids 
(Figure 15). It seems apparent that cell growth and proliferation are differentially 
regulated in cells grown as monolayers compared to 3D cultures. Freyer and Schor 
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reported that cells in the internal layers of MCTS experience an up to 3-fold size 
reduction (Freyer P and Schor PL, 1989). We also observed a significant reduction 
of cell size within spheroids and organoids. Interestingly, the cells within a MCTS 
proliferate approximately 5-times slower compared to the same cell line grown two-
dimensionally. We determined the doubling time (DT) of NCI-H1437 cells grown as 
monolayer (47h) and grown as spheroids (244h). Consequentially, we assume that 
the DT of cells within MCTOs is even longer. It was reported by several groups that, 
at least for breast, colon and lung cancer, tumor volume doubling time (TVDT) in vivo 
is between 80-250 days (Friberg S and Mattson S, 1997; Spratt JS et al., 1996; 
Spratt JS and Spratt TL, 1964; Arai T et al., 1994).  
 
After longer growth periods (8-16 days) the growth curves of all cell lines started to 
flatten out and declined. Since oxygen and nutrient supply is controlled by diffusion 
sufficient supply can only be ensured for cells residing in the spheroid’s periphery 
(viable rim). Therefore in the spheroids’ integrity might be lost after longer incubation 
periods.  
 
 
 Microarray Analyses reveal differential Gene Expression in 3D 5.2
 
The cell’s pattern of gene expression determines its phenotype and function. 
Exploiting GeneChip human mapping assay technology (Affymetrix) provided us 
insight of differential gene expression in HCC827 and NCI-H1975 lung 
adenocarcinoma cell lines. We could show that gene expression patterns were 
significantly altered when the cells were grown three-dimensionally (Table 6 A, B).  
 
In general we found that immunomodulatory proteins such as complement factor B 
and H are up-regulated in 3D. Lipocalin 2 which preserves Matrixmetalloproteinase 
(MMP)-9 activity and MMP-9 itself are up-regulated in 3D. It was reported that the 
increased expression of metalloproteinase (MMP)-9 promotes the invasive behavior 
of tumor cells (Paret C et al., 2010).  
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A remarkable number of genes encoding for small nucleolar RNAs (snoRNAs) are 
differentially expressed in MCTOs compared to monolayer cultured cells. These non-
coding RNAs might promote oncogenesis as reviewed recently (Williams GT and 
Farzaneh F, 2012).  
 
We currently perform pathway analyses using the Ingenuity software (Ingenuity 
Systems). This might help us to link deregulated genes with oncogenic pathways.  
 
 
 Three-Dimensionality alters Phosphorylation Patterns  5.3
 
Due to posttranslational modifications (PTMs) of proteins, a cell’s proteome can 
consist of three fold more protein isoforms than the number of genes encoding them. 
These PTMs are essential to fine-tune signaling pathways of which many of those 
control proliferation and cell survival (Alberts B et al., 2008; Mann M and Jensen ON, 
2003). A frequent reversible post-translational modification that plays a central role in 
tumorigenesis is phosphorylation. For this purpose it is essential to determine the 
phosphorylation patterns of certain protein panels known to be involved in 
tumorigenesis (Mann M and Jensen ON, 2003).  
 
Cancer cells are strongly dependent on growth promoting signals for continuous 
oncogenesis. These signals are predominantly growth factors that bind receptor 
tyrosine kinase receptors e.g. epidermal growth factor receptor (EGFR) on the cell-
membrane. It has been reported that non–small-cell lung cancer (NSCLC) frequently 
overexpresses the epidermal growth factor receptor (EGFR) encoded by ErbB-1 
(Arteaga CL, 2002; Bunn PA Jr. and Franklin W, 2002). It was reported by different 
groups that various mutations in the EGFR tyrosine kinase domain lead to 
hyperactivation of the downstream signaling. Takayuki Kosaka reported in 2004 that 
more than 45% of lung cancer patients with EGFR mutations carry an E746-A750 
deletion on exon 19 (Kosaka T et al., 2004). This most frequent exon 19 deletion, 
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that flanks the ATP-binding pocket, which is important for tyrosine kinase activity, 
leads to EGFR pathway hyperactivation. Therefore inhibitors targeting these 
receptors were recently developed and clinically approved. First promising data 
indicate that these targeted therapies may play a crucial role in the future treatment 
of cancer patients.  
To investigate the therapeutic effect of targeted anti-cancer agents we used two 
cancer cell lines carrying EGFR mutations (HCC827, NCI-H1975) of known activities 
while the other two cell lines express wild-type EGFRs. The impact of three-
dimensionality on the cells could therefore be evaluated in this model upon treating 
the cells with the EGFR inhibitor Gefitinib (Iressa). In addition, conventional 
chemotherapeutics were used to monitor their effect in the 3D model  
(Figures 31).  
 
The 10-fold EGFR amplification, the E746-A750 deletion and the 9-fold higher 
pEGFR levels in HCC827 cell line could lead ultimately to oncogene addiction and 
hence to an increased sensitivity to RTKIs such as Gefitinib than wild-type. Using our 
three-dimensional model system we could show that this oncogene addiction in 
HCC827 was only detectable in 3D culture. While only 39% of 2D cultured cells died 
from Gefitinib treatment (10 µM) 91% of spheroids and 78% of organoids died either 
by necrosis or apoptosis after 96h treatment (Figure 31).  
 
Furthermore, a phosphorylated form of the epidermal growth factor receptor 1 
(EGFR) was higher expressed (47-fold) in CaLu-1 organoids compared to 2D cell 
monolayer. EGFR stimulates downstream cell signaling cascades that influence 
beside others cell proliferation, migration and tumorigenesis. The remarkably high 
expression of this receptor in CaLu-1 MCTOs perfectly correlates with the highly 
invasive phenotype observed microscopically (Figures 15-17, 29).  
 
Apart from EGFR, a phosphorylated form of receptor tyrosine kinase Tie-2 was 
higher expressed in organoids compared to conventional cell monolayer in (CaLu-1 
7-fold; HCC827 21-fold). Tie-2 has been reported to play an important role in 
Discussion 
 
 
 
Nico Jacobi  100/111 
vasculogenesis (Mitsuhashi N et al., 2003). EphA receptor 6 (EphA6) was up-
regulated in organoids compared to conventional cell monolayer (CaLu-1 6-fold; 
HCC827 11-fold). Eph receptors are reported to influence down-regulation of cell-cell 
adhesion in cancer cells (Pasquale EB, 1997). Phosphorylated hepatocyte growth 
factor receptor (HGFR) was higher expressed in all cell lines except NCI-H1975 
(CaLu-1 7-fold; HCC827 7-fold, NCI-H1437 14-fold). In cancer HGFRs have been 
implicated in angiogenesis, proliferation, survival, invasion and metastasis (Sattler M 
et al., 2011).  
 
Taken together, we could demonstrate an increased phosphorylation of crucial 
signaling proteins associated in tumorigenesis when cells were cultured three-
dimensionally. Since these PTMs are essential to regulate cancer-associated 
signaling pathways we conclude that  
 
 
 Chemotherapeutics and Molecularly Targeted Treatment  5.4
 
It may seem as if chemotherapy is still the treatment modality for the majority of 
cancers today. We tested two prominent members of this drug class, named 
paclitaxel and cisplatin (Cis-DDP), in our model and determined its efficacy 
compared to monolayer culture. In HC827 cells paclitaxel showed the best activity in 
organoids. Cis-DDP showed only at the highest concentrations therapeutic effects in 
our model (Figure 30). This might be ascribable to the lower overall proliferation rate 
(Figure 32) and by increased cell-cell contacts within the spheroids.  
While the EC50 for paclitaxel treatment of CaLu-1 organoids was 54 µM, even at 
concentrations below 100 nM a strong inhibitory effect on the invasion potential was 
visible (Figure 29). The cell line’s typical infiltration branches that are usually formed 
were completely distorted at this concentration.  
 
We hypothesized earlier that the 10-fold EGFR amplification and the E746-A750 
deletion in HCC827 cells could be an indication for oncogene addition. This could 
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lead to an increased sensitivity to Gefitinib, an EGFR inhibitor. In fact this cell line 
showed highest sensitivity for Gefitinib. HCC827 organoids showed significant higher 
sensitivity for this RTKI compared to cells grown as monolayer. While 61% of two-
dimensionally grown cells survived the highest RTKI concentration of 10 µM only 
91% of spheroids and 78% of organoids were dead (Figure 31).  
 
Taken together we assume that not necessarily sustained proliferation but EGFR 
mediated survival in lung cancer cells, plays a pivotal role in the sensitivity for 
targeted therapies. By inhibiting EGFR signaling especially in association with PI3K 
action the absence of sustained pro-survival stimuli induces apoptosis. This case of 
oncogene addiction which was only observable in three-dimensional cultures depicts 
the physiology of this model system.  
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 Conclusion 6
 
We established various methods to generate complex cell-based 3D cancer models 
on the basis of the human tumor spheroid methodology. 27 different lung, breast and 
colon cancer cell lines were phenotypically characterized within this model in several 
natural and synthetic matrices. In addition we constructed heterotypic co-cultures of 
lung cancer cells and stromal cells that stably express fluorescent proteins. Thereby 
we could demonstrate the influence of stromal cells on the invasive potential of 
cancer cells. Furthermore we implemented a standardized work flow for the 
production of 3D cancer models. Liquid handling robotics and high-content 
phenotype based screenings could enable HTS of millions of compounds within this 
3D model system in the future.  
 
We could show significant differences in gene expression and phosphorylation 
patterns in 2D and 3D cell cultures. Using phospho-proteome profiler antibody arrays 
we found a remarkable increase in RTK phosphorylation, especially in epidermal 
growth factor receptor (EGFR) signal transduction. In line with these findings the 3D 
models exhibited a significantly increased sensitivity to the targeted EGFR inhibitor 
Gefitinib (Iressa). Interestingly, in the clinic it could be demonstrated that the survival 
of lung cancer cells in cancer patients was strictly dependent on hyperactivated 
EGFR signaling (oncogene addiction). Treatment with Gefitinib induced apoptosis in 
cancer cells and caused the shrinkage of the tumors. Hence the organotypic models 
fully mimicked the in vivo situation whereas the 2D cultures were only marginally 
affected by the drug. 
 
Taken together, we propose that 3D tumor models will play a major role in future 
drug discovery. However, much more work is clearly needed in order to fully exploit 
organotypic 3D models for basic and applied cancer research and personalized 
medicine.  
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